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Unless stated otherwise, all reactions were carried out under argon atmosphere in flame dried Schlenk 
glassware. The solvents were purified by distillation over the indicated drying agents under argon: THF, 
Et2O (Mg/anthacene), hexanes (Na/K), EtOH, MeOH (Mg), 1,2-dichloroethane, CD2Cl2, EtOAc, THP (CaH2), 
2-butanone (B2O3). DMF, MeCN and Et3N were dried by an absorption solvent purification system based 
on molecular sieves. 1,2-Dichloroethane, CD2Cl2, THP and 2-butanone were degassed via freeze-pump-
thaw procedure (3 x) and stored over molecular sieves (except 2-butanone). Flash chromatography: 
Merck Geduran silica gel 60 (40 – 63 µm). TLCs were stained with KMnO4, anisaldehyde or PMA.  
NMR spectra were recorded on Bruker DPX 300, AMX 300, AV 400 or AV III 600 spectrometers in the 
solvents indicated; chemical shifts are given in ppm relative to TMS, coupling constants (J) in Hz. The 
solvent signals were used as references and the chemical shifts converted to the TMS scale (CDCl3: δC = 
77.16 ppm; residual CHCl3: δH = 7.26 ppm; CD2Cl2: δC = 54.00 ppm; residual CHDCl2: δH = 5.32 ppm; C6D6: 
δC = 128.06 ppm; residual C6HD5 : δH = 7.16 ppm). Proton and carbon assignments were established using 
HSQC, HMBC and NOESY experiments.  
IR: Alpha Platinum ATR (Bruker), wavenumbers (ṽ) in cm-1. 
MS (EI): Finnigan MAT 8200 (70 eV), ESI-MS: ESQ 3000 (Bruker) or Thermo Scientific LTQ-FT or Thermo 
Scientific Exactive. HRMS: Bruker APEX III FT-MS (7 T magnet) or MAT 95 (Finnigan) or Thermo Scientific 
LTQ-FT or Thermo Scientific Exactive. GC-MS was measured on a Shimadzu GCMS-QP2010 Ultra 
instrument.  
Headspace GC-FID samples were measured on an Agilent Technology 6890 or 7890 with a 30 m HP-plot 
Al2O3 column (0.25 mm ∅, 5 µm film) using H2 as the carrier gas. Headspace GC/MS samples were 
measured on an Agilent Technology 7890A instrument with AT 5975C MSD detection.  
Unless stated otherwise, all commercially available compounds (abcr, Acros, TCI, Aldrich, Alfa Aesar) 
were used as received. The ruthenium complexes [Cp*RuCl]4,
[ 1 ] [Cp*Ru(cod)Cl],[1] and 
[Cp*Ru(NCMe)3][PF6]








Figure S1. The structure of cyclopropane 4e in the solid state; only one of the two independent 
molecules in the unit cell is shown, H-atoms are omitted for clarity 
X-ray Crystal Structure Analysis of Compound 4e: C22 H37 N O3 S Si, Mr = 423.67 g · mol
-1, colorless plate, 
crystal size 0.131 x 0.052 x 0.042 mm3, monoclinic, space group P21, a = 6.835(2) Å, b = 17.816(5) Å, c = 
19.511(6) Å,  = 93.141(6)°, V = 2372.2(12) Å3, T = 150(2) K, Z = 4, Dcalc = 1.186 g · cm
3,  = 0.71073 Å, 
(Mo-K) = 0.208 mm-1, Gaussian absorption correction (Tmin = 0.98, Tmax = 0.99), Bruker-AXS Kappa 
Mach3 APEX-II diffractometer, 2.985 <  < 35.156°, 79614 measured reflections, 20656 independent 
reflections, 15380 reflections with I > 2σ(I), Rint = 0.066. 
The structure was solved by direct methods and refined by full-matrix least-squares against F2 to R1 = 
0.045 [I > 2(I)], wR2 = 0.100, 521 parameters. The H atoms were refined using a riding model, S = 1.070, 
absolute structure parameter = 0.03(2), residual electron density 0.3 (0.73 Å from O2)/ -0.3 (0.55 Å from 







Figure S2. The structure of cycloalkene 12b in the solid state; H-atoms are omitted for clarity. 
X-ray Crystal Structure Analysis of Compound 12b: C16 H23 N O3 S, Mr = 309.41 g · mol
-1, colorless plate, 
crystal size 0.177 x 0.087 x 0.048 mm3, triclinic, space group P1¯, a = 7.9011(18) Å, b = 8.0298(19) Å, c = 
14.549(3) Å,  = 91.943(4)°,  = 98.836(4)°,  = 118.012(4)°, V = 799.2(3) Å3, T = 160(2) K, Z = 2, Dcalc = 
1.286 g · cm
3,  = 0.71073 Å, (Mo-K) = 0.212 mm-1, Gaussian absorption correction (Tmin = 0.98, Tmax = 
0.99), Bruker-AXS Kappa Mach3 APEX-II diffractometer, 2.976 <  < 36.474°, 37819 measured 
reflections, 7683 independent reflections, 5904 reflections with I > 2σ(I), Rint = 0.035. 
The structure was solved by direct methods and refined by full-matrix least-squares against F2 to R1 = 
0.042 [I > 2(I)], wR2 = 0.120, 194 parameters. The H atoms were refined using a riding model, S = 1.031, 





HEADSPACE GC ANALYSES 
The reactions were setup as described in the Experimental Section (see below). After completion of the 
reaction, the mixture was allowed to cool to room temperature and a needle connected to a gas tight 
analysis bag was pierced through the septum used to seal the Schlenk tube. The headspace gases were 
transferred by purging the Schlenk tube into the gas bag by a stream of argon (approx. 50 mL). An aliquot 
of the gas mixture was immediately analyzed by GC-FID and GC-MS. Retention times and fragmentation 
patterns of the analytes were compared with reference samples (“Phillips 40”), which unambiguously 
confirmed the formation of propane/propene from enyne 1f and of isobutane/isobutene from enyne 1e 




















THE BRIDGED CARBENOID 16 
A. Variable-temperature NMR Control of the Stoichiometric Reaction of Enyne 1f with [Cp*RuCl]4 
under H2. [Cp*RuCl]4 (16.1 mg, 0.015 mmol) was added to a stirred solution of enyne 1f (13.9 mg, 
0.059 mmol) in CD2Cl2 (0.7 mL) under argon in a flame-dried Schlenk tube. The mixture was transferred 
into a flame-dried J-Young-NMR tube under argon before it was cooled to −78 °C (dry ice/acetone bath). 
The atmosphere was exchanged for H2 by purging the system with a H2 for 2 min and the NMR tube was 
quickly sealed in a H2 current. The NMR tube was shaken before being introduced into the NMR 
spectrometer, the internal temperature of which had been set to 50°C. 1H NMR spectra were recorded 
at temperatures from −50 °C to room temperature using 10 °C intervals (series of 1H excerpts see Fig. 
S4).  
 
Figures S4 and S5: The formation of the metathesis product 11a starts at −30 °C (signals C + D) with 
steady increase of conversion upon raising the temperature in increments of 10°C. An additional signal (E) 
appears in parallel which was attributed to the bridged carbenoid 16. Conversion was incomplete even at 
room temperature, likely because of insufficient H2 in solution and slow transfer from the gas phase. 
 
B. Room Temperature NMR Spectra of a Stoichiometric Reaction of Enyne 1f with [Cp*RuCl]4 under H2. 
[Cp*RuCl]4 (15.3 mg, 0.014 mmol) was added to a stirred solution of enyne 1f (14.5 mg, 0.062 mmol) in 
CD2Cl2 (0.7 mL) under argon in a flame dried Schlenk tube at room temperature. H2 was bubbled gently 
through the mixture for 2 min and stirring was continued for 30 min under a H2 atmosphere. The mixture 
was transferred into a flame dried J-Young-NMR tube under argon, sealed and immediately analyzed. 
 
Figures S7-S10: The spectra show complete conversion of enyne 1f (signals A + B missing) to product 11a 
(signals C + D). Significant quantities of bridged carbenoid 16 are detected (approx. 15% by comparison of 
signals D and E). 13C NMR, HSQC and HMBC spectra were recorded to characterize the carbenoid species; 





Figure S4: Low and room temperature stoichiometric NMR experiments. Shown is the relevant region in 
the 1H spectra recorded at the specified temperatures (complete spectra see below). Excerpt 1 (top) 
refers to experiment B, excerpts 2 – 8 refer to experiment A. 
 
 




Figure S6. 1H NMR spectra of low temperature stoichiometric NMR experiment A. Spectra are stacked 





Figure S7. 1H NMR spectrum of room temperature stoichiometric NMR experiment B; peak-picking and 
integrals shown for signals attributed to carbenoid 16. 
 
Figure S8: 13C NMR spectrum of the room temperature stoichiometric NMR experiment B; peak-picking 





Figure S9: HSQC of experiment B, cross-peaks for carbenoid 16 are indicated 
 





Figure S11: Synthesis of bridged carbenoid 16 from 2-diazopropane. 
 
Independent Synthesis. 2-Diazopropane (0.2 M in Et2O, 92 µL, 0.02 mmol)
[3][4] was added dropwise to a 
stirred solution of [Cp*RuCl]4 (10 mg, 0.01 mmol) in CH2Cl2 (0.4 mL) at 0 °C in a flame-dried Schlenk tube 
under argon. The mixture was stirred for 1 min before it was allowed to warm to room temperature. The 
solvent was removed by purging with argon and subsequent evacuation of the tube, and the green 
residue was dissolved in CD2Cl2 and immediately analyzed.  
Figures S12-S14: Identical sets of 1H and 13C resonances (Figs. S12 – S13) were found as for the in-situ 
generated carbenoid 16 from NMR experiment B by metathesis, thus strongly supporting the structural 
assignment. nOe data confirm the shown 3D structure, which is also consistent with a previously reported 
dimeric carbenoid.[5]  
 
Figure S12: 1H NMR spectrum of the crude reaction mixture comprising carbenoid 16 prepared by 






Figure S13: HMBC of carbenoid 16 generated from diazopropane 
 





A compilation of side products identified in the reactions of the shown substrates is presented in Table 
S1. As can be seen from entry 1 and 2 the scope of hydrogenative cyclopropanation is limited by the 
higher propensity of such substrates to get activated either by allylic substitution (entry 1) or oxidative 
cyclization (entry 2) of the terminal alkene compared to the internal alkenes used for hydrogenative 
metathesis. Oxidative enyne cyclization can also be observed by the “competition”-substrate (entry 3) 
where the non-hydrogenative cyclization outcompetes carbene formation by gem-hydrogenation. 
Products of oxidative cyclization were also observed with 1,2-disubstituted enynes (entries 4 and 5). 
Finally, a propargylic alcohol (entry 6) yielded a mixture of products formed by hydrogenative 
metathesis, trans-hydrogenation and enyne addition/isomerization. 
Table S1: Identified side products formed upon treatment of the shown substrates under 






Tetrahydrofuran-2-ol (S1). DIBAL-H (1 M in CH2Cl2, 34.8 mL, 34.8 mmol) was slowly added to a solution of 
γ-butyrolactone (2.5 g, 29.0 mmol) in CH2Cl2 (12 mL) at −78 °C and stirring was continued 
for 1.5 h at that temperature. MeOH (3 mL) and sat. Rochelle salt solution (3 mL) were 
introduced, the mixture was warmed to room temperature and vigorously stirred for 2 h until clean 
separation of the layers was reached. The aqueous phase was extracted with CH2Cl2 (3 x 25 mL) and the 
combined organic layers were dried over MgSO4. The solvent was removed under reduced pressure and 
the crude product was used without further purification (colorless oil, 1.06 g, 41%). 1H NMR (400 MHz, 
CDCl3) δ 5.53 (dd, J = 4.4, 1.6 Hz, 1H), 4.04 (td, J = 7.7, 7.2, 4.9 Hz, 1H), 3.89 – 3.80 (m, 1H), 2.12 – 1.99 
(m, 1H), 1.99 – 1.80 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 98.5, 67.5, 33.3, 23.6. The spectral data is 
consistent with previously reported values.[6] 
5-Methylhex-4-en-1-ol (S2). KOtBu (1.16 g, 10.4 mmol dissolved in 7.7 mL THF) was added to a 
suspension of isopropyltriphenylphosphonium iodide (4.1 g, 9.5 mmol) in THF 
(10.0 mL) at −78 °C. The mixture was warmed to 0 °C and stirred for 30 min at that 
temperature before a solution of lactol S1 (0.76 g, 8.63 mmol) in THF (4.2 mL) was 
introduced. The mixture was stirred at room temperature for 18 h before water (10 mL) and Et2O (50 mL) 
were added and the layers were separated. The aqueous phase was extracted with Et2O (2 x 50 mL) and 
the combined organic layers were dried over MgSO4. The solvent was removed under reduced pressure 
and the residue was purified by flash chromatography (silica, pentane/Et2O 7:3) to furnish the product as 
a colorless liquid (444 mg, 45%). 1H NMR (400 MHz, CDCl3) δ 5.13 (tdq, J = 7.2, 2.9, 1.4 Hz, 1H), 3.64 (t, 
J = 6.5 Hz, 2H), 2.11 – 2.02 (m, 2H), 1.69 (q, J = 1.3 Hz, 3H), 1.65 – 1.57 (m, 5H), 1.40 (br, 1H). 13C NMR 
(101 MHz, CDCl3) δ 132.4, 124.0, 62.9, 32.9, 25.9, 24.5, 17.8. The spectral data is consistent with 
previously reported values.[7]  
6-Bromo-2-methylhex-2-ene (S3). Br2 (0.38 mL, 7.2 mmol) was added dropwise to a solution of PPh3 
(2.0 g, 7.7 mmol) and imidazole (870 mg, 12.7 mmol) in CH2Cl2 (13.6 mL) at 0 °C. 
The mixture was stirred for 15 min before alcohol S2 (440 mg, 3.9 mmol) was 
added at 0 °C. Stirring was continued for 45 min at 0 °C and for another 1 h at room 
temperature. The suspension was successively washed with H2O2 solution (3 % H2O2 in water, 2 x 3 mL) 
and aq. Na2S2O3 solution (1 M, 2 x 10 mL). The combined thiosulfate layers were extracted with CH2Cl2 (2 
x 40 mL) and the combined organic layers were dried over MgSO4. The solvent was removed under 
reduced pressure. The solid residue was suspended in hexanes (20 mL) by means of short ultrasonication 
and the resulting suspension filtered through a short plug of silica, thoroughly rinsing with hexanes 
(200 mL). The combined filtrates were concentrated under reduced pressure to give the product as a 
colorless liquid (622 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 5.07 (tdq, J = 7.3, 2.9, 1.3 Hz, 1H), 3.40 (t, 
J = 6.7 Hz, 2H), 2.13 (q, J = 7.1 Hz, 2H), 1.89 (p, J = 6.9 Hz, 2H), 1.70 (q, J = 1.3 Hz, 3H), 1.63 (d, J = 1.3 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 133.3, 122.6, 33.8, 33.0, 26.6, 25.9, 17.9. The spectral data is consistent 
with previously reported values.[8] 
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4-Methylpent-4-en-1-ol (S4). LiAlH4 (570 mg, 15 mmol) was added in portions to a solution of ethyl 4-
methylpent-4-enoate (1.1 g, 7.5 mmol) in Et2O (8 mL) at 0 °C. The mixture was stirred 
room temperature for 4 h before water (0.52 mL) and NaOH (0.52 mL, 15% in water) 
was carefully added. The mixture was stirred for 15 min at room temperature before more water 
(0.85 mL) was added. Stirring was continued for 15 min, the suspension was filtrated through a glas frit, 
the residue was washed with Et2O (20 mL) and the combined filtrates were dried over Na2SO4. The 
solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (silica, pentane/Et2O 2:1) to give the title compound as a colorless liquid (502 mg, 66%). 
1H NMR (400 MHz, CDCl3) δ 4.72 (s, 1H), 4.71 (s, 1H), 3.65 (t, J = 6.5 Hz, 2H), 2.10 (t, J = 7.6 Hz, 2H), 1.76 – 
1.67 (m, 5H), 1.53 – 1.44 (br, 1H). 13C NMR (101 MHz, CDCl3) δ 145.7, 110.3, 62.9, 34.2, 30.7, 22.5. The 
spectral data is consistent with previously reported values.[9] 
5-Bromo-2-methylpent-1-ene (S5). Br2 (0.49 mL, 9.5 mmol) was added dropwise to a solution of PPh3 
(2.6 g, 10.0 mmol) and imidazole (1.13 g, 16.5 mmol) in CH2Cl2 (17.7 mL) at 0 °C. The 
mixture was stirred for 15 min before alcohol S4 (502 mg, 5.0 mmol) was added at 
0 °C. Stirring was continued for 45 min at 0 °C and for 1 h at reach room temperature. The suspension 
was washed H2O2 solution (3 % H2O2 in water, 2 x 4 mL) and Na2S2O3 solution (1 M, 2 x 15 mL). The 
combined thiosulfate layers were extracted with CH2Cl2 (2 x 50 mL) and the combined organic layers 
were dried over MgSO4. The solvent was removed under reduced pressure. The solid white residue was 
suspended in hexanes (20 mL) by means of short ultrasonication and insoluble material filtered off 
through a short plug of silica. The filter cake and silica were thoroughly rinsed with hexanes (200 mL) and 
the combined filtrates were concentrated under reduced pressure to give the product as a colorless 
liquid (427 mg, 52%). 1H NMR (400 MHz, CDCl3) δ 4.80 – 4.73 (m, 1H), 4.75 – 4.69 (m, 1H), 3.41 (t, 
J = 6.7 Hz, 2H), 2.20 – 2.12 (m, 2H), 2.04 – 1.94 (m, 2H), 1.75 – 1.69 (m, 3H). 13C NMR (101 MHz, CDCl3) 
δ 144.1, 111.2, 36.2, 33.5, 30.7, 22.5. The spectral data is consistent with previously reported values.[10] 
Pent-1-en-3-ol (S6). Freshly distilled propionaldehyd (2.42 g, 41.7 mmol) in Et2O (42 mL) was added over 
30 min to a stirred solution of vinylmagnesium bromide (1 M in THF, 50 mL, 50 mmol) at 
−78 °C. The mixture was stirred for 1 h at −78 °C before it was allowed to reach room 
temperature. The mixture was acidified with aqueous HCl (1 M, 55 mL) and the layers were 
separated. The aqueous phase was extracted with Et2O (3 x 100 mL) and the combined organic layers 
were washed with brine and dried over MgSO4. The solvent was removed under reduced pressure to give 
the crude product as a pale yellow liquid, which was used without further purification (3.28 g, 91%) 
1H NMR (400 MHz, CDCl3) δ 5.86 (ddd, J = 16.9, 10.4, 6.2 Hz, 1H), 5.22 (dt, J = 17.2, 1.4 Hz, 1H), 5.16 – 
5.07 (m, 1H), 4.08 – 3.98 (m, 1H), 1.63 – 1.50 (m, 3H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 141.1, 114.9, 74.7, 30.0, 9.7. The spectral data is consistent with previously reported values.[11] 
Methyl (E)-hept-4-enoate (S7). Alcohol S6 (3.28 g, 38.0 mmol) was added to trimethylorthoacetate 
(14.5 mL, 114 mmol) and propionic acid (140 mg, 1.9 mmol) in a thick-walled 
pressure Schlenk flask. The flask was sealed and immersed into a pre-heated oil 
bath at 120 °C and the mixture stirred at this temperature for 14 h. The mixture 
was cooled to room temperature before being reheated to 120 °C in air. After reaching room 
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temperature, the solution was diluted with CH2Cl2 (50 mL) and aqueous HCl (1 M, 10 mL) and the mixture 
was stirred for 1 h before the layers were separated. The aqueous phase was extracted with CH2Cl2 (2 x 
100 mL), the combined organic layers were washed with sat. NaHCO3 solution and dried over MgSO4. The 
solvent was removed under reduced pressure and the resulting crude product used without further 
purification (colorless oil, 4.77 g, 88%). 1H NMR (400 MHz, CDCl3) δ 5.51 (dtt, J = 14.9, 6.0, 1.1 Hz, 1H), 
5.38 (dtt, J = 15.2, 6.2, 1.4 Hz, 1H), 3.67 (s, 3H), 2.42 – 2.33 (m, 2H), 2.34 – 2.26 (m, 2H), 2.05 – 1.93 (m, 
2H), 0.95 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.9, 133.5, 127.0, 51.6, 34.3, 28.0, 25.7, 13.9. 
The spectral data is consistent with previously reported values.[12] 
(E)-Hept-4-en-1-ol (S8). LiAlH4 (1.87 g, 49 mmol) was added in portions to a solution of ester S7 (2.0 g, 
14.1 mmol) in Et2O (44 mL) at 0 °C. The mixture was stirred at room 
temperature for 4 h before water (2 mL) and NaOH (2 mL, 15% in water) were 
carefully added. The mixture was stirred for 15 min before more water (6 mL) was added. Stirring was 
continued for another 15 min, the suspension was filtrated through a glas frit, the residue was washed 
with Et2O (20 mL) and the combined filtrates were dried over Na2SO4. The solvent was removed under 
reduced pressure and the resulting crude product used without further purification (colorless liquid, 
1.49 g, 93%). 1H NMR (400 MHz, CDCl3) δ 5.54 – 5.46 (m, 1H), 5.47 – 5.34 (m, 1H), 3.65 (t, J = 6.5 Hz, 2H), 
2.11 – 2.03 (m, 2H), 2.03 – 1.95 (m, 2H), 1.68 – 1.59 (m, 2H), 0.96 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 132.9, 128.6, 62.8, 32.6, 29.0, 25.7, 14.1. The spectral data is consistent with previously 
reported values.[13] 
(E)-7-Bromohept-3-ene (S9). Br2 (0.72 mL, 14.0 mmol) was added dropwise to a solution of PPh3 (3.86 g, 
14.7 mmol) and imidazole (1.65 g, 24.3 mmol) in CH2Cl2 (26 mL) at 0 °C. The 
mixture was stirred for 15 min before alcohol S8 (840 mg, 7.4 mmol) was added 
at 0 °C. Stirring was continued for 45 min at 0 °C and at room temperature for 1 h. The suspension was 
washed H2O2 solution (3 % H2O2 in water, 2 x 6 mL) and Na2S2O3 solution (1 M, 2 x 20 mL). The combined 
thiosulfate layers were extracted with CH2Cl2 (2 x 80 mL) and the combined organic layers dried over 
MgSO4. The solvent was removed under reduced pressure. The white residue was suspended in hexanes 
(30 mL) by means of short ultrasonication and insoluble materials were filtered off through a plug of 
silica. The filter cake and silica were thoroughly rinsed with hexanes (300 mL) and the combined filtrate 
were concentrated under reduced pressure to give the title compound as a colorless liquid (1.06 g, 82%). 
1H NMR (400 MHz, CDCl3) δ 5.52 (dtt, J = 15.3, 6.2, 1.3 Hz, 1H), 5.34 (dtt, J = 15.1, 6.7, 1.5 Hz, 1H), 3.41 (t, 
J = 6.8 Hz, 2H), 2.14 (dddd, J = 8.6, 7.5, 6.1, 1.3 Hz, 2H), 2.00 (qdq, J = 7.5, 6.4, 1.2 Hz, 2H), 1.91 (p, 
J = 7.0 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 133.9, 127.0, 33.5, 32.6, 31.0, 25.7, 
14.0. The spectral data is consistent with previously reported values.[13] 
4-Methylpent-1-en-3-ol (S10). Freshly distilled isobutyraldehyd (3.02 g, 41.7 mmol) in Et2O (44 mL) was 
added over 30 min to a stirred solution of vinylmagnesium bromide (1 M in THF, 50 mL, 
50 mmol) at −78 °C. The mixture was stirred for 1 h at −78 °C before being allowed to 
reach room temperature. The mixture was acidified with aqueous HCl (1 M, 55 mL) and the 
layers were separated. The aqueous phase was extracted with Et2O (3 x 100 mL) and the combined 
organic layers were washed with brine and dried over MgSO4. The solvent was removed under reduced 
S21 
 
pressure and the resulting crude product used without further purification (light yellow liquid, 3.75 g, 
90%). 1H NMR (400 MHz, CDCl3) δ 5.86 (ddd, J = 17.1, 10.4, 6.4 Hz, 1H), 5.22 (dt, J = 17.2, 1.5 Hz, 1H), 5.15 
(ddd, J = 10.4, 1.7, 1.1 Hz, 1H), 3.88 – 3.83 (m, 1H), 1.80 – 1.67 (m, 1H), 0.93 (d, J = 6.8 Hz, 3H), 0.90 (d, 
J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 139.6, 115.7, 78.4, 33.7, 18.3, 17.9. The spectral data is 
consistent with previously reported values.[14] 
Methyl (E)-6-methylhept-4-enoate (S11). Alcohol S10 (3.75 g, 37.4 mmol) was added to 
trimethylorthoacetate (14.3 mL, 112 mmol) and propionic acid (138 mg, 
1.9 mmol) in a thick-walled pressure Schlenk flask. The sealed flask was 
immersed in a heating bath at 120 °C and the mixture stirred for 14 h. The 
mixture was allowed to cool to room temperature and then stirred again at 120 °C open to air. After 
reaching ambient temperature, the solution was diluted with CH2Cl2 (50 mL) and aqueous HCl (1 M, 
10 mL). The mixture was stirred for 1 h at room temperature before the layers were separated and the 
aqueous phase extracted with CH2Cl2 (2 x 100 mL). The combined organic layers were washed with sat. 
NaHCO3 solution and dried over MgSO4. The solvent was removed under reduced pressure and the 
resulting crude product was used without further purification in the next step (colorless oil, 5.45 g, 93%). 
1H NMR (400 MHz, CDCl3) δ 5.43 (ddt, J = 15.4, 6.2, 1.0 Hz, 1H), 5.34 (dtd, J = 15.3, 6.0, 1.0 Hz, 1H), 3.66 
(s, 3H), 2.40 – 2.33 (m, 2H), 2.33 – 2.26 (m, 2H), 2.26 – 2.17 (m, 1H), 0.95 (d, J = 6.8 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 173.9, 139.1, 125.0, 51.6, 34.4, 31.1, 28.0, 22.7. 
(E)-6-Methylhept-4-en-1-ol (S12). LiAlH4 (1.7 g, 45 mmol) was added in portions to a solution of ester 
S11 (2.0 g, 12.8 mmol) in Et2O (40 mL) at 0 °C. The mixture was warmed to room 
temperature and stirring was continued for 4 h before water (2 mL) and NaOH 
(2 mL, 15% in water) were carefully added. The mixture was stirred for 15 min 
at room temperature before more water (6 mL) was added. After stirring for additional 15 min, the 
suspension was filtrated through a glass frit, the residue was washed with Et2O (20 mL) and the 
combined filtrates were dried over Na2SO4. The solvent was removed under reduced pressure and the 
resulting crude material used in the next step without further purification (colorless liquid, 1.65 g, 100%). 
1H NMR (400 MHz, CDCl3) δ 5.47 – 5.32 (m, 2H), 3.65 (t, J = 6.5 Hz, 2H), 2.30 – 2.17 (m, 1H), 2.11 – 2.03 
(m, 2H), 1.69 – 1.57 (m, 2H), 0.96 (d, J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 138.5, 126.5, 62.8, 32.6, 
31.1, 29.0, 22.8. The spectral data is consistent with previously reported values.[15] 
(E)-7-Bromo-2-methylhept-3-ene (S13). Br2 (0.67 mL, 13.0 mmol) was added dropwise to a solution of 
PPh3 (3.60 g, 13.7 mmol) and imidazole (1.54 g, 22.6 mmol) in CH2Cl2 (24 mL) at 
0 °C. The mixture was stirred for 15 min before alcohol S12 (880 mg, 6.9 mmol) 
was added at 0 °C. Stirring was continued for 30 min at 0 °C and for 1 h at 
ambient temperature. The suspension was washed with H2O2 solution (3 % H2O2 in water, 2 x 6 mL) and 
Na2S2O3 solution (1 M, 2 x 20 mL). The combined thiosulfate layers were extracted with CH2Cl2 (2 x 80 mL) 
and the combined organic phases were dried over MgSO4. The solvent was removed under reduced 
pressure. The solid white residue was suspended in hexanes (30 mL) by means of short ultrasonication 
and the suspension filtered through a plug of silica. The filter cake and silica were thoroughly rinsed with 
hexanes (300 mL) and the combined filtrates were evaporated to give the product as a colorless liquid 
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(1.08 g, 83%). 1H NMR (400 MHz, CDCl3) δ 5.45 (ddt, J = 15.3, 6.5, 1.3 Hz, 1H), 5.30 (dtd, J = 15.3, 6.7, 1.2 
Hz, 1H), 3.40 (t, J = 6.8 Hz, 2H), 2.31 – 2.17 (m, 1H), 2.18 – 2.07 (m, 2H), 1.91 (p, J = 7.0 Hz, 2H), 0.96 (d, 
J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 139.5, 124.9, 33.5, 32.7, 31.2, 31.0, 22.7. 
(E)-6-Bromohex-2-ene (S14). Br2 (1.86 mL, 36.3 mmol) was added dropwise to a solution of PPh3 (10.1 g, 
38.5 mmol) and imidazole (4.4 g, 64.1 mmol) in CH2Cl2 (75 mL) at 0 °C. The mixture 
was stirred for 15 min before trans-4-hexen-1-ol (2.14 g, 21.4 mmol) was added at 
0 °C. Stirring was continued for 45 min at 0 °C and at room temperature for another 30 min. The 
suspension was washed with H2O2 solution (3 % H2O2 in water, 2 x 15 mL) and Na2S2O3 solution (1 M, 2 x 
30 mL). The combined thiosulfate layers were extracted with CH2Cl2 (2 x 80 mL) and the combined 
extracts were dried over MgSO4. The solvent was evaporated, the solid residue was suspended in 
hexanes (30 mL) by means of short ultrasonication and the suspension filtered through a plug of silica. 
The filter cake and silica were thoroughly rinsed with hexanes (300 mL), the combined filtrates were 
evaporated to give the title compound as a colorless liquid (1.56 g, 45%). 1H NMR (400 MHz, CDCl3) 
δ 5.50 (dqt, J = 14.8, 6.1, 1.2 Hz, 1H), 5.37 (dtq, J = 15.1, 6.9, 1.5 Hz, 1H), 3.40 (t, J = 6.8 Hz, 2H), 2.13 (m, 
2H), 1.90 (p, J = 6.7 Hz, 2H), 1.65 (dq, J = 6.3, 1.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 129.3, 126.6, 33.5, 
32.6, 31.0, 18.1. The spectral data is consistent with previously reported values.[16] 
(Z)-6-Bromohex-2-ene (S15). Prepared analogously from cis-4-hexen-1-ol (1.0 g, 10.0 mmol) as a 
colorless liquid (1.10 g, 68%). 1H NMR (400 MHz, CDCl3) δ 5.52 (dddd, J = 10.7, 8.3, 6.8, 
5.2 Hz, 1H), 5.38 – 5.29 (m, 1H), 3.41 (t, J = 6.7 Hz, 2H), 2.26 – 2.17 (m, 2H), 1.92 (dq, 
J = 8.1, 6.7 Hz, 2H), 1.64 (ddt, J = 6.8, 1.8, 0.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
128.5, 125.7, 33.6, 32.6, 25.4, 13.0. The spectral data is consistent with previously reported values.[17]  
5-Methylhex-4-enal (S16). 2-Methyl-3-buten-2-ol (8.0 g, 93 mmol), ethyl vinyl ether (17.8 mL, 186 mmol) 
and H3PO4 (85%, 0.1 mL, 1.4 mmol) were stirred in a sealed thick-walled pressure 
Schlenk flask for 2.5 h at 150 °C. The mixture was cooled to room temperature before 
Et3N (0.6 mL, 4.2 mmol) was added. The crude product was purified by distillation 
under reduced pressure (60 mbar, 120 °C bath temperature). The product was obtained as a colorless oil 
by collecting the fraction boiling at 72 °C (2.38 g, 23%). 1H NMR (400 MHz, CDCl3) δ 9.76 (t, J = 1.8 Hz, 
1H), 5.09 (tdq, J = 7.1, 2.9, 1.5 Hz, 1H), 2.48 – 2.43 (m, 2H), 2.37 – 2.26 (m, 2H), 1.69 (q, J = 1.3 Hz, 3H), 
1.63 (s, 3H).13C NMR (101 MHz, CDCl3) δ 202.8, 133.4, 122.3, 44.1, 25.8, 21.1, 17.9. The spectral data is 
consistent with previously reported values.[18] 
1-((tert-Butyldimethylsilyl)oxy)propan-2-one (S17). Imidazole (1.0 g, 14.8 mmol) was added in portions 
to a stirred solution of hydroxyacetone (90%, 555 mg, 6.7 mmol) and TBSCl (1.53 g, 
10.1 mmol) in CH2Cl2 (26 mL) at 0 °C. The mixture was stirred at room temperature for 
1 h before brine (10 mL) was added. The layers were separated, the aqueous phase was 
extracted with CH2Cl2 (2 x 50 mL) and the combined organic layers were dried over MgSO4. The solvent 
was evaporated and the crude product purified by flash chromatography (silica, pentane/Et2O 20:1 – 
10:1) to give the title compound as a colorless oil (1.1 g, 88%). 1H NMR (400 MHz, CDCl3) δ 4.14 (s, 2H), 
2.17 (s, 3H), 0.92 (s, 9H), 0.09 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 209.4, 69.7, 26.1, 25.9, 18.4, -5.4. The 
spectral data is consistent with previously reported values.[19] 
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4-((tert-Butyldimethylsilyl)oxy)butan-2-one (S18). Imidazole (3.2 g, 47.1 mmol) was added in portions to 
a stirred solution of 4-hydroxy-2-butanone (90%, 2.1 g, 21.5 mmol) and TBSCl (4.85 g, 
32.2 mmol) in CH2Cl2 (83 mL) at 0 °C. The mixture was stirred at room temperature 
for 1 h before brine (20 mL) was added and the layers were separated. The aqueous 
phase was extracted with CH2Cl2 (2 x 100 mL) and the combined organic layers were dried over MgSO4. 
The solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (silica, pentane/Et2O 20:1 – 10:1) to give the title compound as a colorless oil (4.05 mg, 
93%). 1H NMR (400 MHz, CDCl3) δ 3.88 (t, J = 6.3 Hz, 1H), 2.61 (t, J = 6.3 Hz, 1H), 2.18 (s, 1H), 0.87 (s, 4H), 
0.05 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 208.2, 59.0, 46.7, 31.0, 26.0, 18.4, -5.3. The spectral data is 
consistent with previously reported values.[20] 
 
Alkyne Building Blocks 
 
The alkynes S19,[21] S20,[22] S21,[23] and S22[24] were prepared according to literature procedures 
1-Ethynyl-1-(methoxymethoxy)cyclohexane (S23). A solution of 1-ethynyl-1-cyclohexanol (4.0 g, 
32.2 mmol) in THF (15 mL) was added to a stirred suspension of NaH (1.55 g, 
64.4 mmol) in THF (65 mL) at 0 °C. The mixture was stirred for 30 min at room 
temperature before MOMCl (0.61 mL, 8.1 mmol) was added at 0 °C. Stirring was 
continued for 2 h at room temperature before aq. sat. NH4Cl (6 mL), water (4 mL) and tert-butyl methyl 
ether (80 mL) were added. The aqueous phase was extracted with tert-butyl methyl ether (2 x 100 mL) 
and the combined organic layers were washed with brine and dried over MgSO4. The solvent was 
evaported and the residue purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1) to give 
the title compound as colorless oil (5.06 g, 93%). 1H NMR (400 MHz, CDCl3) δ 4.94 (s, 2H), 3.40 (s, 3H), 
2.52 (s, 1H), 2.01 – 1.91 (m, 2H), 1.73 – 1.48 (m, 7H), 1.33 – 1.18 (m, 1H). 13C NMR (101 MHz, CDCl3) 
δ 92.9, 84.9, 74.8, 74.7, 56.0, 38.6, 25.4, 23.0. IR (film) ṽ 3305, 3264, 2934, 1149, 1023 cm-1. HRMS (ESI+) 
for C10H16O2 [M+Na]
+: calcd: 191.1042, found: 191.1042. 
tert-Butyl((1-ethynylcyclohexyl)oxy)dimethylsilane (S24). TBSOTf (0.83 mL, 3.6 mmol) was added to a 
solution of 1-ethynyl-1-cyclohexanol (500 mg, 4.0 mmol) and 2,6-lutidine (0.94 mL, 
8.1 mmol) in CH2Cl2 (10.8 mL) at 0 °C. The mixture was stirred for 2 h before water 
(2 mL) was added. After reaching room temperature, the layers were separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with 
brine and dried over MgSO4. The solvent was removed under reduced pressure and the crude product 
was purified by flash chromatography (silica, hexanes) to yield the title compound as a colorless oil 
(610 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 2.45 (s, 1H), 1.84 – 1.74 (m, 2H), 1.71 – 1.57 (m, 4H), 1.57 – 
1.47 (m, 2H), 1.47 – 1.38 (m, 1H), 1.37 – 1.25 (m, 1H), 0.88 (s, 9H), 0.17 (s, 6H). 13C NMR (101 MHz, CDCl3) 
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δ 88.7, 72.8, 69.2, 41.2, 26.0, 25.4, 22.8, 18.3, -2.7. IR (film) ṽ 3310, 2932, 2856, 1252, 1101, 835, 774 cm-
1. HRMS (ESI+) for C14H26OSi [M+H]
+: calcd: 239.1826, found: 239.1825. 
N-(4-(1-Methoxycyclohexyl)but-3-yn-1-yl)-4-methylbenzenesulfonamide (S25). n-BuLi (1.6 M in 
hexanes, 2.0 mL, 3.2 mmol) was slowly added to a solution of alkyne S19 
(400 mg, 2.9 mmol) in THF (5.0 mL) at 0 °C. A solution of N-tosylaziridine 
(428 mg, 2.2 mmol) in THF (3.3 mL) and DMPU (0.9 mL) was slowly added and 
the mixture was stirred at room temperature for 3 h. sat. NH4Cl solution 
(2 mL), water (2 mL) and EtOAc (20 mL) were introduced before the layers 
were separated and the aqueous phase extracted with EtOAc (2 x 50 mL). The combined organic layers 
were washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and 
the crude product was purified by flash chromatography (silica, hexanes/EtOAc 5:1 – 4:1 – 3:1) to give 
the title compound as a colorless oil (405 mg, 56%). 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.73 (m, 2H), 7.34 
– 7.29 (m, 2H), 4.71 (t, J = 6.3 Hz, 1H), 3.28 (s, 3H), 3.10 (q, J = 6.5 Hz, 2H), 2.45 – 2.39 (m, 5H), 1.84 – 1.74 
(m, 2H), 1.68 – 1.57 (m, 2H), 1.57 – 1.36 (m, 5H), 1.34 – 1.23 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 143.7, 
137.1, 129.9, 127.2, 84.0, 81.9, 74.0, 50.7, 42.2, 36.9, 25.5, 22.9, 21.7, 20.1. IR (film) ṽ 3283 (br), 2933, 
2857, 1446, 1090 cm-1. HRMS (ESI+) for C18H25NO3S [M+Na]
+: calcd: 358.1447, found: 358.1444. 
4-Methyl-N-(3-methylbut-2-en-1-yl)-N-(prop-2-yn-1-yl)benzenesulfonamide (S26). 1-Bromo-3-methyl-
2-butene (0.66 mL, 5.7 mmol) was added to a solution of N-tosylpropargylamine 
(1.00 g, 4.8 mmol)[25] and K2CO3 (1.32 g, 9.6 mmol) in MeCN (8 mL). The mixture 
was stirred at 60 °C for 6 h before it was cooled to room temperature and diluted 
with MeCN (10 mL). The suspension was filtered through a pad of Celite and the filter cake was washed 
with EtOAc (40 mL). The combined filtrates were evaporated and the crude product was purified by flash 
chromatography (silica, hexanes/EtOAc 10:1 – 6:1 – 4:1) to give the title compound as a colorless oil 
(923 mg, 70%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.71 (m, 2H), 7.31 – 7.27 (m, 2H), 5.10 (tdq, J = 7.2, 
2.8, 1.4 Hz, 1H), 4.07 (d, J = 2.5 Hz, 2H), 3.81 (d, J = 7.3 Hz, 2H), 2.42 (s, 3H), 1.98 (t, J = 2.5 Hz, 1H), 1.72 
(q, J = 1.1 Hz, 3H), 1.67 (d, J = 1.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 143.5, 139.2, 136.3, 129.5, 128.0, 
118.1, 77.2, 73.5, 44.1, 35.5, 26.0, 21.7, 18.0. The spectral data is consistent with previously reported 
values.[26] 
Dimethyl 2-(3-methylbut-2-en-1-yl)-2-(prop-2-yn-1-yl)malonate (S27). Cs2CO3 (1.45 g, 4.5 mmol) and 1-
bromo-3-methyl-2-butene (0.67 mL, 5.8 mmol) were added to a solution of 
malonate S21 (330 mg, 1.9 mmol) in acetone (12.8 mL). The mixture was stirred at 
reflux temperature for 18 h before it was allowed to cool to room temperature 
and diluted with tert-butyl methyl ether (40 mL). The mixture was filtered through a pad of Celite and 
the filter cake was washed with tert-butyl methyl ether (100 mL). The combined filtrates were 
evaporated and the crude product was purified by flash chromatography (silica, hexanes/tert-butyl 
methyl ether 1:0 – 20:1 – 10:1 – 6:1) to give the title compound as a colorless oil (412 mg, 89%). 1H NMR 
(400 MHz, CDCl3) δ 4.89 (tdq, J = 7.3, 2.9, 1.4 Hz, 1H), 3.73 (s, 6H), 2.80 – 2.76 (m, 4H), 2.00 (t, J = 2.7 Hz, 
1H), 1.70 (q, J = 1.2 Hz, 3H), 1.66 – 1.64 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 170.6, 137.1, 117.1, 79.4, 
71.3, 57.3, 52.9, 30.9, 26.2, 22.7, 18.1. The spectral data is consistent with previously reported values.[27] 
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3-Methylbut-2-en-1-yl propiolate (S28). Propiolic acid (500 mg, 7.1 mmol) and 1-bromo-3-methyl-2-
butene (1.65 mL, 14.3 mmol) were added to a stirred suspension of NaHCO3 
(1.2 g, 14.3 mmol) in DMF (8.8 mL) at room temperature. The mixture was stirred 
for 18 h before it was diluted with water (60 mL) and Et2O (30 mL). The aqueous 
phase was extracted with Et2O (2 x 30 mL) and the combined organic layers were washed with water 
(60 mL) and dried over MgSO4. The solvent was removed under reduced pressure and the crude product 
was purified by flash chromatography (silica, pentane/Et2O 10:1) to give the title compound as a 
colorless oil (993 mg, quant.). 1H NMR (400 MHz, CDCl3) δ 5.37 (tdq, J = 7.2, 2.9, 1.5 Hz, 1H), 4.69 (dt, 
J = 7.4, 0.8 Hz, 2H), 2.85 (s, 1H), 1.80 – 1.74 (m, 3H), 1.75 – 1.70 (m, 3H). 13C NMR (101 MHz, CDCl3) 
δ 152.91, 140.95, 117.46, 74.90, 74.57, 63.22, 25.93, 18.21. IR (film) ν 3271, 2975, 2937, 2119, 1707 cm-1. 
HRMS (ESI+) for C8H10O2 [M+H]
+: calcd: 139.0734, found: 139.0754. 
 
Preparation of the Substrates for Hydrogenative Cyclopropanation or Metathesis 
1-(6-Methylhept-5-en-1-yn-1-yl)cyclohexan-1-ol (S29). n-BuLi (1.6 M in hexanes, 3.2 mL, 5.1 mmol) was 
added to a solution of 1-ethynyl-1-cyclohexanol (315 mg, 2.5 mmol) in THF 
(6.9 mL) and DMPU (2.6 mL) at 0 °C in a thick-walled pressure Schlenk 
flask. The mixture was stirred for 1 h at 0 °C before 5-bromo-2-methyl-2-
pentene (0.28 mL, 2.1 mmol) in THF (1.7 mL) was added. The flask was 
sealed and the mixture stirred at 65 °C for 16 h. Water (2 mL) and tert-butyl methyl ether (5 mL) were 
added and the layers were separated. The aqueous phase was extracted with tert-butyl methyl ether (3 x 
20 mL) and the combined organic layers were washed with brine and dried over MgSO4. The solvent was 
removed under reduced pressure and the crude product was purified by flash chromatography (silica, 
hexanes/EtOAc 10:1 – 7:1 – 5:1) to give the title compound as a colorless oil (50 mg, 11%). 1H NMR 
(400 MHz, CDCl3) δ 5.21 – 5.11 (m, 1H), 2.26 – 2.15 (m, 4H), 1.90 – 1.80 (m, 2H), 1.77 – 1.61 (m, 2H), 1.70 
(d, J = 1.3 Hz, 3H), 1.63 (d, J = 1.3 Hz, 3H), 1.60 – 1.46 (m, 6H), 1.29 – 1.14 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 133.0, 123.1, 84.8, 84.0, 69.0, 40.4, 27.8, 25.9, 25.4, 23.6, 19.3, 18.0. IR (film) ṽ 3357 (br), 2930, 
2856, 1446, 1057, 962 cm-1. HRMS (ESI+) for C14H22O [M+Na]
+: calcd: 229.1563, found: 229.1564. 
1-Methoxy-1-(6-methylhept-6-en-1-yn-1-yl)cyclohexane (S30). n-BuLi (1.6 M in hexanes, 1.08 mL, 
1.74 mmol) was slowly added to a solution of alkyne S19 (200 mg, 
1.45 mmol) in THF (5 mL) at 0 °C. The mixture was stirred for 30 min at 
0 °C before a solution of alkyl bromide S5 (283 mg, 1.74 mmol) in THF 
(3.3 mL) and DMPU (0.9 mL) was added. The mixture was warmed to 
room temperature and stirring was continued stirring for 18 h. sat. NH4Cl solution (2 mL), tert-butyl 
methyl ether (10 mL) and water (2 mL) were added and the layers were separated. The aqueous phase 
was extracted with tert-butyl methyl ether (3 x 20 mL) and the combined organic layers were washed 
with brine and dried over MgSO4. The solvent was removed and the residue was purified by flash 
chromatography (silica, hexanes/EtOAc 1:0 – 80:1 – 40:1) to give the title compound as a colorless oil 
(203 mg, 64%). 1H NMR (400 MHz, CDCl3) δ 4.73 (m, 1H), 4.70 (m, 1H), 3.35 (s, 3H), 2.24 (t, J = 7.0 Hz, 
2H), 2.13 (t, J = 7.6 Hz, 2H), 1.91 – 1.81 (m, 2H), 1.72 (dd, J = 1.4, 0.8 Hz, 3H), 1.71 – 1.59 (m, 4H), 1.59 – 
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1.46 (m, 5H), 1.34 – 1.23 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 145.2, 110.6, 86.3, 81.5, 74.2, 50.6, 37.2, 
37.00, 27.1, 25.7, 23.1, 22.5, 18.4. IR (film) ṽ 3074, 2933, 2857, 1650, 1447, 1093 cm-1. HRMS (ESI+) for 
C15H24O [M+Na]
+: calcd: 243.1719, found: 243.1720. 
1-(Hept-6-en-1-yn-1-yl)-1-methoxycyclohexane (1a). A detailed procedure as well as analytical and 
spectroscopic data of this compound and copies of the spectra are 
contained in the Supporting Information of our previous 
publication.[28] 
(E)-1-Methoxy-1-(oct-6-en-1-yn-1-yl)cyclohexane (1b). n-BuLi (1.6 M in hexanes, 1.08 mL, 1.74 mmol) 
was slowly added to a solution of alkyne S19 (200 mg, 1.45 mmol) in 
THF (5 mL) at 0 °C. The mixture was stirred for 30 min at 0 °C before a 
solution of alkyl bromide S14 (283 mg, 1.74 mmol) in THF (3.3 mL) and 
DMPU (0.9 mL) was added. The mixture was then stirred at room 
temperature for 18 h. sat. NH4Cl solution (2 mL), tert-butyl methyl ether (10 mL) and water (2 mL) were 
added and the layers were separated. The aqueous phase was extracted with tert-butyl methyl ether (3 x 
20 mL) and the combined organic layers were washed with brine and dried over MgSO4. The solvent was 
removed under reduced pressure and the residue was purified by flash chromatography (silica, 
hexanes/EtOAc 1:0 – 80:1 – 40:1) to give the title compound as a colorless oil (204 mg, 64%). 1H NMR 
(400 MHz, CDCl3) δ 5.52 – 5.35 (m, 2H), 3.35 (s, 3H), 2.23 (t, J = 7.1 Hz, 2H), 2.14 – 2.05 (m, 2H), 1.85 (t, 
J = 8.3 Hz, 2H), 1.69 – 1.45 (m, 12H), 1.26 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 130.5, 125.8, 86.4, 81.3, 
74.2, 50.6, 37.2, 31.8, 28.9, 25.7, 23.1, 18.2, 18.1. IR (film) ṽ 2932, 2856, 1447, 1092 cm-1. HRMS (ESI+) for 
C15H24O [M+Na]
+: calcd: 243.1719, found: 243.1721. 
(Z)-1-Methoxy-1-(oct-6-en-1-yn-1-yl)cyclohexane (1c). Prepared analogously as a colorless oil (184 mg, 
58%). 1H NMR (400 MHz, CDCl3) δ 5.54 – 5.44 (m, 1H), 5.43 – 5.31 (m, 1H), 
3.35 (s, 3H), 2.25 (t, J = 7.0 Hz, 2H), 2.22 – 2.11 (m, 2H), 1.91 – 1.82 (m, 
2H), 1.69 – 1.46 (m, 12H), 1.33 – 1.24 (m, 1H). 13C NMR (101 MHz, CDCl3) 
δ 129.7, 124.9, 86.4, 81.3, 74.2, 50.6, 37.2, 28.9, 26.1, 25.7, 23.1, 18.3, 
12.9. IR (film) ṽ 3013, 2933, 2857, 1446, 1092 cm-1. HRMS (ESI+) for C15H24O [M+Na]
+: calcd: 243.1719, 
found: 243.1720. 
(E)-1-Methoxy-1-(non-6-en-1-yn-1-yl)cyclohexane (1d). n-BuLi (1.6 M in hexanes, 1.08 mL, 1.74 mmol) 
was added slowly to a solution of alkyne S19 (200 mg, 1.45 mmol) in 
THF (5 mL) at 0 °C. The mixture was stirred for 30 min at 0 °C before 
a solution of alkyl bromide S9 (308 mg, 1.74 mmol) in THF (3.3 mL) 
and DMPU (0.9 mL) was added. The mixture was stirred at ambient 
temperature for 18 h. sat. NH4Cl solution (2 mL), tert-butyl methyl ether (10 mL) and water (2 mL) were 
added and the layers were separated. The aqueous phase was extracted with tert-butyl methyl ether (3 x 
20 mL) and the combined organic layers were washed with brine and dried over MgSO4. The solvent was 
removed under reduced pressure and the residue purified by flash chromatography (silica, 
hexanes/EtOAc 1:0 – 80:1 – 40:1) to furnish the product as a colorless oil (193 mg, 57%). 1H NMR 
(400 MHz, CDCl3) δ 5.53 – 5.44 (m, 1H), 5.43 – 5.31 (m, 1H), 3.35 (s, 3H), 2.23 (t, J = 7.1 Hz, 2H), 2.15 – 
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2.04 (m, 2H), 2.06 – 1.94 (m, 2H), 1.90 – 1.82 (m, 2H), 1.70 – 1.46 (m, 9H), 1.33 – 1.24 (m, 1H), 0.97 (t, 
J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 133.1, 128.2, 86.4, 81.3, 74.2, 50.6, 37.2, 31.8, 29.0, 25.8, 
25.7, 23.1, 18.2, 14.1. IR (film) ṽ 2932, 2856, 2822, 1447, 1092 cm-1. HRMS (ESI+) for C16H26O [M+Na]
+: 
calcd: 257.1876, found: 257.1876. 
(E)-1-Methoxy-1-(8-methylnon-6-en-1-yn-1-yl)cyclohexane (1e). n-BuLi (1.6 M in hexanes, 1.08 mL, 
1.74 mmol) was added slowly to a solution of alkyne S19 (200 mg, 
1.45 mmol) in THF (5 mL) at 0 °C. The mixture was stirred for 30 min 
at 0 °C before a solution of alkyl bromide S13 (332 mg, 1.74 mmol) in 
THF (3.3 mL) and DMPU (0.9 mL) was introduced. The mixture was 
stirred at room temperature for 18 h. sat. NH4Cl solution (2 mL), tert-butyl methyl ether (10 mL) and 
water (2 mL) were added and the layers were separated. The aqueous phase was extracted with tert-
butyl methyl ether (3 x 20 mL) and the combined organic layers were washed with brine and dried over 
MgSO4. The solvent was evaporated and the crude product purified by flash chromatography (silica, 
hexanes/EtOAc 1:0 – 80:1 – 40:1) to give the product as a colorless oil (216 mg, 60%). 1H NMR (400 MHz, 
CDCl3) δ 5.41 (ddt, J = 15.3, 6.1, 1.0 Hz, 1H), 5.32 (dtd, J = 15.3, 6.4, 0.9 Hz, 1H), 3.35 (s, 3H), 2.23 (t, 
J = 7.1 Hz, 2H), 2.24 (m, 1H), 2.09 (m, 2H), 1.90 – 1.82 (m, 2H), 1.70 – 1.46 (m, 9H), 1.28 (m, 1H), 0.96 (d, 
J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 138.8, 126.1, 86.4, 81.3, 74.2, 50.6, 37.2, 31.8, 31.2, 29.0, 
25.7, 23.1, 22.8, 18.2. IR (film) ṽ 2932, 2858, 2822, 1448, 1093 cm-1. HRMS (ESI+) for C17H28O [M+Na]
+: 
calcd: 271.2032, found: 271.2032. 
1-Methoxy-1-(7-methyloct-6-en-1-yn-1-yl)cyclohexane (1f). n-BuLi (1.6 M in hexanes, 1.08 mL, 
1.74 mmol) was slowly added to a solution of alkyne S19 (200 mg, 
1.45 mmol) in THF (5 mL) at 0 °C. The mixture was stirred for 30 min at 
0 °C before a solution of alkyl bromide S3 (307 mg, 1.74 mmol) in THF 
(3.3 mL) and DMPU (0.9 mL) was added. The mixture was warmed to 
room temperature and stirring was continued for 18 h. Sat. NH4Cl 
solution (2 mL), tert-butyl methyl ether (10 mL) and water (2 mL) were added and the layers were 
separated. The aqueous phase was extracted with tert-butyl methyl ether (3 x 20 mL) and the combined 
organic layers were washed with brine and dried over MgSO4. The solvent was removed under reduced 
pressure and the residue purified by flash chromatography (silica, hexanes/EtOAc 1:0 – 80:1 – 40:1) to 
give the product as a colorless oil (183 mg, 54%). 1H NMR (400 MHz, CDCl3) δ 5.10 (tdq, J = 7.2, 2.9, 
1.5 Hz, 1H), 3.35 (s, 3H), 2.24 (d, J = 7.0 Hz, 2H), 2.09 (q, J = 7.3 Hz, 2H), 1.90 – 1.81 (m, 2H), 1.69 (q, 
J = 1.3 Hz, 3H), 1.65 – 1.60 (m, 2H), 1.62 (s, 3H), 1.59 – 1.47 (m, 7H), 1.26 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 132.4, 123.8, 86.6, 81.2, 74.2, 50.6, 37.2, 29.3, 27.3, 25.9, 25.7, 23.1, 18.4, 17.8. IR (film) ṽ 2932, 
2857, 1446, 1092 cm-1. HRMS (ESI+) for C16H26O [M+Na]




N-Allyl-N-(4-(1-methoxycyclohexyl)but-3-yn-1-yl)-4-methylbenzenesulfonamide (S31). Allyl bromide 
(0.08 mL, 0.95 mmol) was added to a stirred suspension of K2CO3 
(131 mg, 0.95 mmol) and sulfonamide S25 (160 mg, 0.48 mmol) in 
MeCN (0.8 mL) at room temperature. After stirring for 18 h at 60 °C the 
mixture was allowed to cool to ambient temperature and diluted with 
MeCN (10 mL). The suspension was filtered through a plug of cotton 
wool and the filtrate was concentrated under reduced pressure. The crude product was purified by flash 
chromatography (silica, hexanes/EtOAc 20:1 – 10:1 – 6:1) to yield the title compound as a colorless oil 
(105 mg, 59%). 1H NMR (400 MHz, CDCl3) δ 7.75 – 7.68 (m, 2H), 7.33 – 7.28 (m, 2H), 5.66 (ddt, J = 17.1, 
10.1, 6.3 Hz, 1H), 5.23 – 5.14 (m, 2H), 3.85 (dt, J = 6.3, 1.4 Hz, 2H), 3.32 – 3.26 (m, 5H), 2.55 – 2.48 (m, 
2H), 2.43 (s, 3H), 1.86 – 1.76 (m, 2H), 1.67 – 1.42 (m, 7H), 1.35 – 1.23 (m, 1H). 13C NMR (101 MHz, CDCl3) 
δ 143.5, 137.2, 133.2, 129.9, 127.3, 119.2, 83.1, 82.6, 74.0, 51.4, 50.7, 46.5, 36.9, 25.6, 22.9, 21.7, 19.7. 
IR (film) ṽ 2935, 2857, 1449, 1345, 1158, 1092 cm-1. HRMS (ESI+) for C21H29NO3S [M+Na]
+: calcd: 
398.1760, found: 398.1762. 
N-(4-(1-Methoxycyclohexyl)but-3-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide 
(S32). 1-Bromo-3-methyl-2-butene (0.28 mL, 2.4 mmol) was added 
to a stirred suspension of K2CO3 (494 mg, 3.6 mmol) and sulfonamide 
S25 (400 mg, 1.2 mmol) in MeCN (3.8 mL). The mixture was stirred at 
60 °C for 2 h before additional K2CO3 (494 mg, 3.6 mmol) and 1-
bromo-3-methyl-2-butene (0.28 mL, 2.4 mmol) were added. After 
stirring for another 18 h at 60 °C, the mixture was cooled to room temperature and diluted with MeCN 
(10 mL). The suspension was filtered through a plug of cotton wool and the filtrate was evaporated. The 
residue was purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1 – 6:1) to yield the title 
compound as pale yellow oil (306 mg, 64%). 1H NMR (400 MHz, CDCl3) δ 7.71 – 7.66 (m, 2H), 7.32 – 7.27 
(m, 2H), 5.01 (tdq, J = 7.1, 2.8, 1.4 Hz, 1H), 3.82 (d, J = 7.1 Hz, 2H), 3.31 (s, 3H), 3.28 – 3.22 (m, 2H), 2.53 – 
2.47 (m, 2H), 2.42 (s, 3H), 1.85 – 1.77 (m, 2H), 1.66 (q, J = 1.2 Hz, 3H), 1.65 – 1.57 (m, 5H), 1.57 – 1.41 (m, 
5H), 1.32 – 1.22 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 143.3, 137.4, 137.3, 129.7, 127.3, 119.1, 83.0, 82.8, 
74.0, 50.6, 46.5, 46.2, 36.9, 25.9, 25.6, 22.9, 21.6, 19.8, 17.9. IR (film) ṽ 2933, 2857, 1448, 1341, 1157 cm-
1. HRMS (ESI+) for C23H33NO3S [M+Na]
+: calcd: 426.1073, found: 426.2072. 
2-(5-(1-Methoxycyclohexyl)pent-4-yn-1-yl)-1,3-dioxolane (S33). n-BuLi (1.6 M in hexanes, 1.63 mL, 
2.60 mmol) was added slowly to a solution of alkyne S19 (300 mg, 
2.17 mmol) in THF (7.6 mL) at 0 °C. The mixture was stirred for 30 min 
at 0 °C before a solution of 2-(3-bromopropyl)-1,3-dioxolane (508 mg, 
2.60 mmol) in THF (4.9 mL) and DMPU (1.3 mL) was added. The mixture 
was stirred at room temperature for 18 h. sat. NH4Cl solution (3 mL), tert-butyl methyl ether (20 mL) and 
water (3 mL) were added and the layers were separated. The aqueous phase was extracted with tert-
butyl methyl ether (3 x 40 mL) and the combined organic layers were washed with brine and dried over 
MgSO4. The solvent was removed under reduced pressure and the residue purified by flash 
chromatography (silica, hexanes/EtOAc 1:0 – 80:1 – 40:1) to give the product as a colorless oil (301 mg, 
55%). 1H NMR (400 MHz, CDCl3) δ 4.89 (t, J = 4.7 Hz, 1H), 4.01 – 3.92 (m, 2H), 3.90 – 3.81 (m, 2H), 3.34 (s, 
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3H), 2.30 (t, J = 7.0 Hz, 2H), 1.89 – 1.82 (m, 2H), 1.82 – 1.74 (m, 2H), 1.65 (m, 5H), 1.57 – 1.45 (m, 4H), 
1.25 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 104.36, 85.93, 81.62, 74.16, 65.03, 50.63, 37.16, 33.15, 25.70, 
23.61, 23.06, 18.82. IR (film) ṽ 2935, 2859, 1449, 1142, 1091 cm-1. HRMS (ESI+) for C15H24O3 [M+Na]
+: 
calcd: 275.1618, found: 275.1618. 
6-(1-Methoxycyclohexyl)hex-5-ynal (S34). A solution of dioxolane S33 (150 mg, 0.59 mmol) in acetone 
(2.7 mL) was added to a solution of p-TsOH∙H2O (6 mg, 0.03 mmol) in 
water (2.7 mL). The mixture was stirred at 70 °C for 3 h before sat. 
NaHCO3 solution (2 mL) was added. The mixture was diluted with tert-
butyl methyl ether (10 mL) and the layers were separated. The aqueous 
phase was extracted with tert-butyl methyl ether (3 x 30 mL) and the combined organic layers were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1) to give the title 
compound as a colorless oil (110 mg, 89%). 1H NMR (400 MHz, CDCl3) δ 9.81 (t, J = 1.4 Hz, 1H), 3.33 (s, 
3H), 2.59 (td, J = 7.2, 1.4 Hz, 2H), 2.33 (t, J = 6.9 Hz, 2H), 1.90 – 1.80 (m, 4H), 1.69 – 1.59 (m, 2H), 1.59 – 
1.44 (m, 5H), 1.33 – 1.23 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 202.0, 84.9, 82.5, 74.1, 50.6, 43.0, 37.1, 
25.6, 23.0, 21.5, 18.3. IR (film) ṽ 2935, 2857, 1725, 1448, 1091 cm-1. HRMS (ESI+) for C13H20O2 [M+Na]
+: 
calcd: 231.1355, found: 231.1357. 
1-(Methoxymethoxy)-1-(7-methyloct-6-en-1-yn-1-yl)cyclohexane (S35). n-BuLi (1.6 M in hexanes, 
12.2 mL, 19.5 mmol) was slowly added to a solution of alkyne 
S23 (2.73 g, 16.2 mmol) in THF (57 mL) at 0 °C. The mixture was stirred 
for 30 min at 0 °C before a solution of alkyl bromide S3 (3.73 g, 
21.1 mmol) in THF (37 mL) and DMPU (9.8 mL) was added. The 
resulting mixture was stirred at room temperature for 18 h. sat. NH4Cl solution (10 mL), tert-butyl methyl 
ether (50 mL) and water (10 mL) were added, the aqueous phase was extracted with tert-butyl methyl 
ether (3 x 100 mL) and the combined organic layers were washed with brine and dried over MgSO4. The 
solvent was evaporated and the residue purified by flash chromatography (silica, hexanes/EtOAc 1:0 – 
20:1) to give the title compound as a colorless oil (4.12 g, 96%). 1H NMR (400 MHz, CDCl3) δ 5.10 (tdq, 
J = 7.2, 2.9, 1.4 Hz, 1H), 4.94 (s, 2H), 3.39 (s, 3H), 2.23 (t, J = 7.1 Hz, 2H), 2.08 (q, J = 7.4 Hz, 2H), 1.96 – 
1.86 (m, 2H), 1.69 (q, J = 1.3 Hz, 3H), 1.68 – 1.62 (m, 3H), 1.61 (s, 3H), 1.59 – 1.48 (m, 6H), 1.30 – 1.19 (m, 
1H). 13C NMR (101 MHz, CDCl3) δ 132.5, 123.8, 92.9, 87.5, 80.9, 75.5, 55.8, 39.1, 29.2, 27.3, 25.9, 25.6, 
23.4, 18.4, 17.8. IR (film) ṽ 2931, 2857, 1447, 1149, 1026 cm-1. HRMS (ESI+) for C17H28O2 [M+Na]
+: calcd: 
287.1981, found: 287.1980. 
tert-Butyldimethyl((1-(7-methyloct-6-en-1-yn-1-yl)cyclohexyl)oxy)silane (S36). n-BuLi (1.6 M in hexanes, 
1.3 mL, 2.1 mmol) was slowly added to a solution of alkyne 
S24 (412 mg, 1.7 mmol) in THF (6.0 mL) at 0 °C. The mixture was stirred 
for 30 min at 0 °C before a solution of alkyl bromide S3 (398 mg, 
2.2 mmol) in THF (3.9 mL) and DMPU (1.0 mL) was added. The mixture 
was stirred at room temperature for 18 h. sat. NH4Cl solution (3 mL), tert-butyl methyl ether (20 mL) and 
water (2 mL) were added, the aqueous phase was extracted with tert-butyl methyl ether (2 x 30 mL) and 
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the combined organic layers were washed with brine and dried over MgSO4. The solvent was evaporated 
and the residue was purified by flash chromatography (silica, hexanes) to give the title compound as a 
colorless oil (523 mg, 90%). 1H NMR (400 MHz, CDCl3) δ 5.10 (m, 1H), 2.20 (t, J = 7.1 Hz, 2H), 2.08 (q, 
J = 7.4 Hz, 2H), 1.77 – 1.69 (m, 2H), 1.70 (q, J = 1.3 Hz, 3H), 1.67 – 1.59 (m, 2H), 1.62 (s, 3H), 1.59 – 1.45 
(m, 6H), 1.46 – 1.34 (m, 1H), 1.35 – 1.24 (m, 1H), 0.88 (s, 9H), 0.15 (s, 6H). 13C NMR (101 MHz, CDCl3) 
δ 132.4, 123.9, 85.0, 84.9, 69.4, 41.6, 29.1, 27.4, 26.1, 25.9, 25.6, 23.0, 18.5, 18.3, 17.9, -2.7. IR (film) ṽ 
2930, 2855, 1446, 1250, 1095, 1052 cm-1. HRMS (ESI+) for C21H38OSi [M+Na]
+: calcd: 357.2584, found: 
257.2585. 
3-Methylbut-2-en-1-yl 3-(1-hydroxycyclohexyl)propiolate (S37). LiHMDS (1 M in THF, 1.7 mL, 1.7 mmol) 
was slowly added to a solution of alkyne S28 (200 mg, 1.45 mmol) in 
THF (14.1 mL) at −78 °C and the resulting mixture was stirred for 30 min 
at that temperature. Cyclohexanone (0.23 mL, 2.17 mmol) was slowly 
added at −78 °C to the mixture allowed to reach room temperature. 
After 5 min sat., NH4Cl solution (1 mL) and EtOAc (20 mL) were 
introduced, the layers were separated, the aqueous phase was extracted with EtOAc (3 x 30 mL) and the 
combined organic layers were washed with brine and dried over MgSO4. The solvent was evaporated and 
the residue was purified by flash chromatography (silica, hexanes/EtOAc 10:1 – 7:1 – 5:1) to give the title 
compound as a colorless oil (312 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 5.30 (tdq, J = 7.2, 2.9, 1.4 Hz, 1H), 
4.60 (d, J = 7.4 Hz, 2H), 1.92 – 1.84 (m, 2H), 1.70 (d, J = 1.3 Hz, 3H), 1.65 (d, J = 1.3 Hz, 3H), 1.65 – 1.41 (m, 
7H), 1.28 – 1.15 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 153.7, 140.4, 117.6, 90.3, 76.0, 68.5, 62.9, 39.1, 
25.8, 24.9, 22.8, 18.1. IR (film) ṽ 3401 (br), 2935, 2860, 2227, 1709, 1228 cm-1. HRMS (ESI+) for C14H20O3 
[M+Na]+: calcd: 259.1346, found: 259.1304. 
3-Methylbut-2-en-1-yl 3-(1-methoxycyclohexyl)propiolate (S38). A solution of alcohol S37 (300 mg, 
1.27 mmol) in THF (1 mL) was slowly added to a suspension of NaH 
(152 mg, 6.3 mmol) in THF (5.5 mL) at 0 °C. The mixture was stirred for 
10 min at room temperature before MeI (0.80 mL, 12.7 mmol) was 
carefully added at 0 °C. Stirring was continued for 1 h at room 
temperature before water (2 mL) and tert-butyl methyl ether (30 mL) 
were introduced. The aqueous phase was extracted with tert-butyl methyl ether (2 x 50 mL) and the 
combined organic layers were washed with brine and dried over MgSO4. The solvent was evaporated and 
the residue was purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1) to yield the title 
compound as a colorless oil (129 mg, 41%). 1H NMR (400 MHz, CDCl3) δ 5.37 (ddp, J = 8.8, 5.7, 1.4 Hz, 
1H), 4.67 (dt, J = 7.3, 0.9 Hz, 2H), 3.37 (s, 3H), 1.98 – 1.85 (m, 2H), 1.77 (d, J = 1.2 Hz, 3H), 1.73 (d, 
J = 1.3 Hz, 3H), 1.73 – 1.58 (m, 4H), 1.59 – 1.44 (m, 4H), 1.38 – 1.25 (m, 2H). 13C NMR (101 MHz, CDCl3) 
δ 153.8, 140.4, 117.8, 88.5, 77.9, 73.9, 63.0, 51.4, 36.1, 26.0, 25.3, 22.5, 18.2. IR (film) ṽ 2937, 2860, 
2238, 1711, 1230 cm-1. HRMS (ESI+) for C15H23O3 [M+Na]




1-(1-Methoxycyclohexyl)-7-methyloct-6-en-1-yn-3-ol (S39). n-BuLi (1.6 M in hexanes, 3.6 mL, 5.8 mmol) 
was slowly added to a solution of alkyne S19 (800 mg, 5.8 mmol) in THF 
(47 mL) at 0 °C. The mixture was stirred for 30 min at 0 °C before a 
solution of the freshly distilled aldehyde S16 (500 mg, 4.5 mmol) in THF 
(3 mL) was introduced. After warming to room temperature the 
mixture was stirred for 10 min before water (5 mL) and EtOAc (50 mL) 
were added. The layers were separated and the aqueous phase was extracted with EtOAc (2 x 50 mL). 
The combined organic layers were dried over MgSO4 and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1 – 
7:1 - 5:1) to yield the title compound as a colorless oil (647 mg, 58%). 1H NMR (400 MHz, CDCl3) δ 5.14 
(tdq, J = 7.2, 2.9, 1.4 Hz, 1H), 4.44 (t, J = 6.5 Hz, 1H), 3.35 (s, 3H), 2.27 – 2.08 (m, 2H), 1.93 – 1.83 (m, 2H), 
1.81 – 1.67 (m, 2H), 1.70 (q, J = 4.0 Hz, 3H), 1.70 – 1.62 (m, 2H), 1.63 (s, 3H), 1.61 – 1.46 (m, 5H), 1.35 – 
1.23 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 132.8, 123.4, 87.2, 86.1, 74.0, 62.4, 50.8, 38.2, 36.9, 36.8, 25.9, 
25.6, 24.0, 23.0, 17.8. IR (film) ṽ 3416 (br), 2933, 2857, 1446, 1079 cm-1. HRMS (ESI+) for C16H26O2 
[M+Na]+: calcd: 273.1825, found: 273.1823. 
1-Methoxy-1-(3-methoxy-7-methyloct-6-en-1-yn-1-yl)cyclohexane (S40). A solution of alcohol S39 
(200 mg, 0.8 mmol) in THF (1 mL) was added to a stirred suspension of 
NaH (96 mg, 4.0 mmol) in THF (3.2 mL) at 0 °C. The mixture was stirred 
for 10 min at room temperature before MeI (0.50 mL, 8.0 mmol) was 
introduced. After stirring for 1 h at room temperature, sat. NH4Cl 
solution (2 mL), water (4 mL) and tert-butyl methyl ether (30 mL) were 
added and the layers separated. The aqueous phase was extracted with tert-butyl methyl ether (2 x 
30 mL) and the combined organic layers were washed with brine and dried over MgSO4. The solvent was 
removed under reduced pressure and the crude product was purified by flash chromatography (silica, 
hexanes/EtOAc 1:0 – 20:1) to give the title compound as a colorless oil (184 mg, 87%). 1H NMR (400 MHz, 
CDCl3) δ 5.11 (tdq, J = 7.3, 2.9, 1.4 Hz, 1H), 4.00 (t, J = 6.6 Hz, 1H), 3.40 (s, 3H), 3.37 (s, 3H), 2.19 – 2.10 
(m, 2H), 1.95 – 1.86 (m, 2H), 1.82 – 1.71 (m, 2H), 1.69 (d, J = 1.0 Hz, 3H), 1.70 – 1.60 (m, 2H), 1.62 (s, 3H), 
1.60 – 1.47 (m, 5H), 1.35 – 1.19 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 132.6, 123.5, 87.0, 85.1, 74.2, 70.9, 
56.5, 50.8, 37.0, 36.0, 25.9, 25.6, 24.1, 23.1, 17.8. IR (film) ṽ 2934, 2857, 1447, 1290, 1094 cm-1. HRMS 
(EI) for C17H28O2 [M]
+: calcd: 264.1084, found: 264.2085. 
1-(1-Methoxycyclohexyl)-7-methyloct-6-en-1-yn-3-one (S41). NaHCO3 (336 mg, 4.0 mmol) and Dess-
Martin periodinane (508 mg, 1.2 mmol) were added to a solution of 
alcohol S39 (200 mg, 0.8 mmol) in wet CH2Cl2 (7.4 mL) at 0 °C. The 
mixture was stirred at room temperature for 30 min before aq. sat. 
Na2S2O3 (3 mL) and water (3 mL) were added. The layers were 
separated and the aqueous phase was extracted with CH2Cl2 (2 x 
20 mL). The combined organic layers were washed with brine and dried over MgSO4. The solvent was 
evaporated and the residue was purified by flash chromatography (silica, hexanes/EtOAc 1:0 – 30:1 – 
20:1) to give the product as a colorless oil (193 mg, 97%). 1H NMR (400 MHz, CDCl3) δ 5.08 (tdq, J = 7.2, 
2.9, 1.5 Hz, 1H), 3.38 (s, 3H), 2.60 (t, J = 7.2 Hz, 2H), 2.36 (q, J = 7.5 Hz, 2H), 1.99 – 1.88 (m, 2H), 1.70 – 
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1.61 (m, 3H), 1.68 (q, J = 1.4 Hz, 3H), 1.62 (s, 3H), 1.59 – 1.45 (m, 4H), 1.38 – 1.28 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 187.7, 133.5, 122.1, 93.2, 85.1, 74.0, 51.4, 46.0, 36.2, 25.8, 25.4, 23.0, 22.6, 17.8. IR 
(film) ṽ 2934, 2859, 2204, 1676, 1120 cm-1. HRMS (ESI+) for C16H24O2 [M+Na]
+: calcd: 271.1668, found: 
271.1668. 
1-(7,7-Difluorohept-6-en-1-yn-1-yl)-1-methoxycyclohexane (22). A solution of aldehyde S34 (110 mg, 
0.53 mmol) in DMF (2.3 mL) was added to solid PPh3 (277 mg, 
1.06 mmol) and sodium chlorodifluoroacetate (161 mg, 1.06 mmol). 
The mixture was stirred at 100 °C for 10 min before it was allowed to 
reach room temperature. Water (3 mL) and tert-butyl methyl ether 
(10 mL) were added and the layers were separated, the aqueous phase 
was extracted with tert-butyl methyl ether (2 x 10 mL) and the combined organic layers were washed 
with brine (2 mL), H2O2 solution (6% in water, 4 mL) and again brine. The organic layer was dried over 
MgSO4 and the solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography (silica, hexanes/EtOAc 1:0 – 50:1) to give the title compound as a colorless oil (62 mg, 
48%). 1H NMR (400 MHz, CDCl3) δ 4.14 (dtd, J = 25.3, 7.9, 2.5 Hz, 1H), 3.34 (s, 3H), 2.27 (t, J = 7.0 Hz, 2H), 
2.11 (qt, J = 7.6, 1.8 Hz, 2H), 1.89 – 1.78 (m, 2H), 1.71 – 1.43 (m, 9H), 1.34 – 1.23 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 156.5 (dd, J = 287.5, 285.1 Hz), 85.3, 81.7, 77.3 (d, J = 21.6 Hz), 74.0, 50.4, 37.0, 28.6 
(t, J = 2.5 Hz), 25.5, 22.9, 21.3 (d, J = 4.5 Hz), 19.0. 19F NMR (282 MHz, CDCl3) δ -88.8 (d, J = 47.3 Hz), -91.3 
(d, J = 47.4 Hz). IR (film) ṽ 2935, 2859, 1746, 1448, 1229, 1092 cm-1. HRMS (EI) for C14H20F2O [M-H]
+: 
calcd: 241.1398, found: 241.1398. 
1-Methoxy-1-(7-methoxyhept-6-en-1-yn-1-yl)cyclohexane (23). PhLi (1.8 M in n-Bu2O, 0.41 mL, 
0.73 mmol) was slowly added to a solution of 
(methoxymethyl)triphenylphosphonium chloride (263 mg, 
0.77 mmol) in Et2O (3.2 mL) at 0 °C. The mixture was stirred for 
10 min at 0 °C before a solution of aldehyde S34 (80 mg, 0.38 mmol) 
in Et2O (1 mL) was introduced. The mixture was stirred at room temperature for 10 min sat. NH4Cl 
solution (1 mL) and tert-butyl methyl ether (5 mL) were added, the layers were separated and the 
aqueous phase was extracted with tert-butyl methyl ether (3 x 20 mL). The combined organic layers were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the 
residue was purified by flash chromatography (silica, hexanes/EtOAc 1:0 – 20:1) to give the title 
compound as a pale yellow oil (44 mg, 48%). 1H NMR (400 MHz, CDCl3) δ (mixture of E/Z isomers: 54/46) 
6.30 (dt, J = 12.7, 1.2 Hz, 0.54H), 5.90 (dt, J = 6.2, 1.4 Hz, 0.46H), 4.70 (dt, J = 12.6, 7.4 Hz, 0.54H), 4.33 
(td, J = 7.4, 6.2 Hz, 0.46H), 3.57 (s, 1.08H), 3.51 (s, 1.62H), 3.35 (s, s, 3H), 2.24 (t, J = 7.1 Hz, 2H), 2.17 (qd, 
J = 7.4, 1.5 Hz, 0.92H), 2.05 (qd, J = 7.4, 1.2 Hz, 1.08H), 1.90 – 1.80 (m, 2H), 1.68 – 1.45 (m, 9H), 1.33 – 
1.22 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 147.8, 146.8, 105.9, 102.0, 86.6, 86.2, 81.4, 81.2, 74.2, 74.2, 
59.6, 56.1, 50.6, 37.2, 37.2, 30.0, 29.3, 26.9, 25.8, 25.7, 23.3, 23.1, 18.4, 18.0. IR (film) ṽ 2932, 2856, 
1656, 1448, 1210, 1110, 1090 cm-1. HRMS (EI) for C15H24O2 [M]




N-Allyl-N-(4-hydroxy-4-methylpent-2-yn-1-yl)-4-methylbenzenesulfonamide (S42). n-BuLi (1.6 M in 
hexanes, 0.59 mL, 0.94 mmol) was added slowly to a solution of alkyne S20 
(181 mg, 0.73 mmol) in THF (7.6 mL) at 0 °C. The solution was stirred for 30 min 
at 0 °C before acetone (0.75 mL, 10.1 mmol) was introduced. The mixture was 
warmed to room temperature and stirring continued for 30 min. sat. NH4Cl 
solution (3 mL) and EtOAc (30 mL) were added, the layers were separated and the aqueous phase was 
extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and dried over 
MgSO4. The solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (silica, hexanes/EtOAc 2:1 – 1:1) to yield the title compound as a pale yellow 
amorphous solid (72 mg, 32%). 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 7.9 Hz, 
2H), 5.75 (ddt, J = 17.1, 10.0, 6.5 Hz, 1H), 5.32 – 5.22 (m, 2H), 4.10 (s, 2H), 3.82 (dt, J = 6.4, 1.2 Hz, 2H), 
2.43 (s, 3H), 1.45 (br, 1H), 1.27 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 143.7, 136.4, 132.1, 129.7, 128.1, 
120.0, 90.6, 74.8, 64.9, 49.2, 36.1, 31.2, 21.6. IR (neat) ṽ 3510, 2981, 2929, 1598, 1160 cm-1. HRMS (ESI+) 
for C16H22NO3S [M+Na]
+: calcd: 308.1315, found: 308.1316. 
N-Allyl-N-(4-((tert-butyldimethylsilyl)oxy)-4-methylpent-2-yn-1-yl)-4-methylbenzenesulfonamide (S43). 
TBSOTf (54 µL, 0.23 mmol) was added to a solution of alcohol S42 (60 mg, 
0.20 mmol) and 2,6-lutidine (46 µL, 0.39 mmol) in CH2Cl2 (0.6 mL) at −15 °C 
(ice/acetone bath). The mixture was stirred for 2 h before water (0.5 mL) was 
added. After reaching room temperature the layers were separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were washed with 
brine and dried over MgSO4. The solvent was removed under reduced pressure and the crude product 
was purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1) to yield the title compound as a 
colorless amorphous solid (67 mg, 81%). 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.3 Hz, 2H), 7.29 (d, 
J = 7.9 Hz, 1H), 5.74 (ddt, J = 17.1, 10.0, 6.4 Hz, 1H), 5.28 (dq, J = 17.2, 1.4 Hz, 1H), 5.23 (dq, J = 10.1, 
1.2 Hz, 1H), 4.12 (s, 2H), 3.83 (d, J = 6.4 Hz, 2H), 2.41 (s, 3H), 1.21 (s, 6H), 0.82 (s, 9H), 0.05 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 143.5, 136.6, 132.2, 129.7, 127.8, 119.9, 91.1, 75.1, 66.2, 49.1, 36.1, 32.8, 
25.8, 21.6, 18.0, -2.8. IR (film) ṽ 2929, 2856, 1352, 1162, 1042 cm-1. HRMS (ESI+) for C22H35NO3SSi 
[M+Na]+: calcd: 444.1999, found: 444.2001. 
N-allyl-N-(4-methoxy-4-methylpent-2-yn-1-yl)-4-methylbenzenesulfonamide (9a). NaH (62 mg, 
2.60 mmol) was added to a solution of alcohol S42 (320 mg, 1.04 mmol) in THF 
(4.5 mL) at room temperature. The suspension was stirred for 10 min before 
MeI (0.33 mL, 5.20 mmol) was slowly added. Stirring was continued for 1 h 
before water (2 mL) and tert-butyl methyl ether (20 mL) were added. The 
aqueous phase was etracted with tert-butyl methyl ether (2 x 20 mL) and the combined organic phases 
were washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and 
the residue was purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1 – 5:1) to yield the 
title compound as a colorless oil (269 mg, 80%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.70 (m, 2H), 7.33 – 
7.27 (m, 2H), 5.75 (ddt, J = 17.2, 10.0, 6.5 Hz, 1H), 5.32 – 5.22 (m, 2H), 4.15 (s, 2H), 3.83 (dt, J = 6.5, 
1.3 Hz, 2H), 3.12 (s, 3H), 2.42 (s, 3H), 1.20 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 143.6, 136.4, 132.2, 129.7, 
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127.8, 120.0, 87.7, 76.8, 70.3, 51.6, 49.2, 36.1, 28.2, 21.6. IR (film) ṽ 2984, 2934, 1350, 1163, 1075 cm-1. 
HRMS (ESI+) for C17H23NO3S [M+Na]
+: calcd 344.1291, found 344.1293. 
N-Allyl-N-(4-hydroxybut-2-yn-1-yl)-4-methylbenzenesulfonamide (S44). n-BuLi (1.6 M in hexanes, 
1.68 mL, 2.69 mmol) was added slowly to a solution of alkyne S20 (515 mg, 
2.07 mmol) in THF (21 mL) at 0 °C. The solution was stirred for 30 min before 
powdered paraformaldehyde (93 mg, 3.10 mmol) was introduced. After stirring 
for another 2 h at room temperature, the reaction was quenched with NH4Cl 
solution (5 mL) and EtOAc (30 mL). The layers were separated and the aqueous phase was extracted with 
EtOAc (2 x 30 mL). The combined organic layers were washed with brine and dried over MgSO4. The 
solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (silica, hexanes/EtOAc 2:1 – 3:2) to yield the title compound as a light yellow oil 
(310 mg, 54%). 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.72 (m, 2H), 7.34 – 7.29 (m, 2H), 5.73 (ddt, J = 17.1, 
10.0, 6.4 Hz, 1H), 5.32 – 5.21 (m, 2H), 4.10 (t, J = 2.0 Hz, 2H), 3.98 (t, J = 2.0 Hz, 2H), 3.82 (dt, J = 6.4, 
1.3 Hz, 2H), 2.43 (s, 3H), 1.23 (s (br), 1H). 13C NMR (101 MHz, CDCl3) δ 143.8, 136.3, 132.1, 129.5, 128.1, 
120.1, 83.9, 78.7, 50.9, 49.4, 36.2, 21.7. IR (film) ṽ 3510 (br), 2924, 2867, 1432, 1345, 1160 cm-1. HRMS 
(ESI+) for C14H17NO3S [M+Na]
+: calcd 302.0821, found 302.0824. 
N-allyl-N-(4-methoxybut-2-yn-1-yl)-4-methylbenzenesulfonamide (9b). NaH (68 mg, 2.77 mmol) was 
added to a solution of alcohol S44 (310 mg, 1.11 mmol) in THF (4.8 mL) and 
the resulting suspension stirred for 10 min before MeI (0.35 mL, 5.55 mmol) 
was slowly added. Stirring was continued for 1 h before water (2 mL) and tert-
butyl methyl ether (20 mL) were introduced. The layers were separated, the 
aqueous phase was extracted with tert-butyl methyl ether (2 x 20 mL) and the combined organic layers 
were washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and 
the residue was purified by flash chromatography (silica, hexanes/EtOAc 10:1 – 6:1 – 5:1) to yield the 
title compound as a colorless oil (270 mg, 83%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.71 (m, 2H), 7.32 – 
7.27 (m, 2H), 5.74 (ddt, J = 17.1, 10.1, 6.4 Hz, 1H), 5.31 – 5.21 (m, 2H), 4.13 (t, J = 1.9 Hz, 2H), 3.83 (t, 
J = 1.9 Hz, 3H), 3.81 (t, J = 1.3 Hz, 1H), 3.19 (s, 3H), 2.42 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 143.6, 136.2, 
132.1, 129.6, 127.9, 120.0, 81.5, 79.3, 59.7, 57.53, 49.3, 36.2, 21.7. IR (film) ṽ 2984, 2929, 1598, 1447, 
1348, 1162, 1093 cm-1. HRMS (ESI+) for C15H19NO3S [M+Na]
+: calcd 316.0978, found 316.0977. 
N-(4-Hydroxy-4-methylpent-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide (S45). 
n-BuLi (1.6 M in hexanes, 1.35 mL, 2.16 mmol) was slowly added to a solution 
of alkyne S26 (460 mg, 1.66 mmol) in THF (17.5 mL) at 0 °C. The solution was 
stirred for 30 min at 0 °C before acetone (1.22 mL, 16.6 mmol) was 
introduced. After stirring at room temperature for 30 min, sat. NH4Cl 
solution (3 mL) and EtOAc (30 mL) were added, the layers were separated and the aqueous phase was 
extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and dried over 
MgSO4. The solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (silica, hexanes/EtOAc 4:1 – 2:1) to yield the title compound as a light yellow 
amorphous solid (297 mg, 53%). 1H NMR (400 MHz, CDCl3) δ 7.78 – 7.72 (m, 2H), 7.34 – 7.29 (m, 2H), 
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5.11 (ddq, J = 8.8, 5.8, 1.4 Hz, 1H), 4.07 (s, 2H), 3.81 (d, J = 7.3 Hz, 2H), 2.43 (s, 3H), 1.73 (s, 3H), 1.68 (s, 
3H), 1.47 (br, 1H), 1.25 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 143.5, 139.1, 136.6, 129.6, 128.1, 118.1, 90.1, 
75.3, 64.9, 44.1, 35.7, 31.1, 26.0, 21.6, 18.0. IR (film) ṽ 3522, 2979, 2921, 1596, 1327, 1152 cm-1. HRMS 
(ESI+) for C18H25O3S [M+Na]
+: calcd: 358.1447, found: 358.1444. 
N-(4-Methoxy-4-methylpent-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide (S46). 
NaH (38 mg, 1.58 mmol) was added to a solution of alcohol S45 (106 mg, 
0.32 mmol) in THF (1.4 mL) at room temperature. The suspension was 
stirred for 10 min before MeI (0.2 mL, 3.16 mmol) was slowly added. After 
stirring for another 1 h at room temperature, water (1 mL) and tert-butyl 
methyl ether (5 mL) were introduced, the layers were separated, the aqueous phase was etracted with 
tert-butyl methyl ether (2 x 10 mL) and the combined organic layers were washed with brine and dried 
over MgSO4. The solvent was removed under reduced pressure and the crude product was purified by 
flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1 – 5:1) to yield the title compound as a colorless 
oil (106 mg, 96%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.70 (m, 2H), 7.32 – 7.27 (m, 2H), 5.13 (tdq, J = 7.3, 
2.9, 1.3 Hz, 1H), 4.12 (s, 2H), 3.82 (d, J = 7.3 Hz, 2H), 3.11 (s, 3H), 2.41 (s, 3H), 1.73 (d, J = 1.3 Hz, 3H), 1.68 
(d, J = 1.3 Hz, 3H), 1.20 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 143.2, 138.8, 136.5, 129.5, 127.7, 118.1, 87.0, 
77.2, 70.2, 51.5, 43.9, 35.6, 28.0, 25.9, 21.5, 17.9. IR (film) ṽ 2982, 2932, 1738, 1346, 1159 cm-1. HRMS 
(ESI+) for C19H27NO3S [M+Na]
+: calcd: 372.1604, found: 372.1603. 
N-(4-((tert-butyldimethylsilyl)oxy)-4-methylpent-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-yl)-
benzenesulfonamide (S47). TBSOTf (82 µL, 0.36 mmol) was added to a solution of alcohol S45 (100 mg, 
0.30 mmol) and 2,6-lutidine (69 µL, 0.60 mmol) in CH2Cl2 (0.8 mL) at 
−15 °C (ice/acetone bath). Stirring was continued for 2 h before water 
(0.5 mL) was added. After reaching room temperature, the layers were 
separated and the aqueous phase was extracted with CH2Cl2 (3 x 5 mL). 
The combined organic layers were washed with brine and dried over MgSO4. The solvent was removed 
under reduced pressure and the crude product was purified by flash chromatography (silica, 
hexanes/EtOAc 20:1 – 10:1) to yield the title compound as a colorless amorphous solid (126 mg, quant.). 
1H NMR (400 MHz, CDCl3) δ 7.75 – 7.71 (m, 2H), 7.30 – 7.27 (m, 2H), 5.12 (dddd, J = 8.6, 5.7, 2.8, 1.4 Hz, 
1H), 4.09 (s, 2H), 3.81 (d, J = 7.2 Hz, 2H), 2.41 (s, 3H), 1.72 (s, 3H), 1.67 (s, 3H), 1.21 (s, 6H), 0.82 (s, 9H), 
0.05 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 143.1, 138.6, 136.6, 130.0, 127.7, 118.2, 90.5, 75.4, 66.1, 44.0, 
35.7, 32.6, 25.8, 25.6, 21.5, 17.9, 17.9, -3.0. IR (film) ṽ 2929, 2855, 1451, 1343, 1160 cm-1. HRMS (ESI+) for 
C24H39NO3SSi [M+Na]
+: calcd: 472.2312, found: 472.2313. 
N-(4-Hydroxyhex-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide (S48). n-BuLi (1.6 
M in hexanes, 1.35 mL, 2.16 mmol) was added slowly to a solution of 
alkyne S26 (460 mg, 1.66 mmol) in THF (17.5 mL) at 0 °C. The solution was 
stirred for 30 min at 0 °C before freshly distilled propionaldehyde 
(1.20 mL, 16.6 mmol) was introduced. Stirring was continued at room 
temperature for 30 min before sat. NH4Cl solution (3 mL) and EtOAc (30 mL) were added. The layers 
were separated and the aqueous phase was extracted with EtOAc (2 x 30 mL). The combined organic 
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layers were washed with brine and dried over MgSO4, the solvent was removed under reduced pressure 
and the crude product was purified by flash chromatography (silica, hexanes/EtOAc 8:1 – 4:1 – 3:1) to 
yield the title compound as a light yellow oil which was directly used in the subsequent step. 
N-(4-Methoxyhex-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide (S49). A solution 
of alcohol S48 in THF (3 mL) was slowly added to a suspension of NaH 
(214 mg, 8.9 mmol) in THF (7.7 mL) at 0 °C. The mixture was stirred for 
10 min at room temperature before MeI (1.12 mL, 17.9 mmol) was 
carefully added at 0 °C. After stirring for another 1 h at room 
temperature, water (1 mL) and tert-butyl methyl ether (10 mL) were introduced and the layers were 
separated. The aqueous phase was extracted with tert-butyl methyl ether (2 x 50 mL), the combined 
organic layers were washed with brine and dried over MgSO4, the solvent was removed under reduced 
pressure and the crude product was purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1 
– 5:1) to yield the title compound as a colorless oil (235 mg, 40% over two steps). 1H NMR (400 MHz, 
CDCl3) δ 7.76 – 7.71 (m, 2H), 7.30 – 7.26 (m, 2H), 5.12 (tdq, J = 7.1, 2.8, 1.4 Hz, 1H), 4.14 (d, J = 1.8 Hz, 
2H), 3.81 (d, J = 7.3 Hz, 2H), 3.61 (tt, J = 6.3, 1.8 Hz, 1H), 3.18 (s, 2H), 2.41 (s, 3H), 1.72 (d, J = 1.3 Hz, 3H), 
1.67 (d, J = 1.3 Hz, 3H), 1.57 – 1.36 (m, 2H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 143.4, 
139.0, 136.5, 129.6, 127.9, 118.2, 84.1, 79.1, 72.4, 56.4, 44.1, 35.8, 28.6, 26.0, 21.6, 18.0, 9.7. IR (film) ṽ 
2971, 2932, 1449, 1343, 1159 cm-1. HRMS (ESI+) for C19H27NO3S [M+Na]
+: calcd: 372.1604, found: 
372.1604. 
N-(4-Hydroxybut-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide (S50). n-BuLi (1.6 
M in hexanes, 0.59 mL, 0.94 mmol) was slowly added to a solution of alkyne 
S26 (200 mg, 0.72 mmol) in THF (7.6 mL) at −78 °C. The solution was stirred 
for 3 h at −78 °C before powdered paraformaldehyde (28 mg, 0.94 mmol) 
was introduced. After stirring at room temperature for 1 h, sat. NH4Cl 
solution (3 mL) and EtOAc (30 mL) were added, the layers were separated and the aqueous phase was 
extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and dried over 
MgSO4. The solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (silica, hexanes/EtOAc 10:1 – 4:1 – 2:1) to yield the title compound as a light yellow oil 
(159 mg, 72%). 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.72 (m, 2H), 7.34 – 7.28 (m, 2H), 5.10 (tdq, J = 7.2, 
2.9, 1.4 Hz, 1H), 4.07 (t, J = 2.0 Hz, 2H), 3.97 (dt, J = 6.1, 2.0 Hz, 2H), 3.80 (d, J = 7.3 Hz, 2H), 2.43 (s, 3H), 
1.72 (d, J = 1.2 Hz, 3H), 1.67 (d, J = 1.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 143.6, 139.2, 136.4, 129.4, 
128.1, 118.0, 83.5, 79.2, 50.9, 44.2, 35.8, 26.0, 21.7, 18.0. The spectral data is consistent with previously 
reported values.[29] 
N-(4-Methoxybut-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide (S51). A solution 
of alcohol S50 (150 mg, 0.49 mmol) in THF (2 mL) was slowly added to a 
suspension of NaH (59 mg, 2.4 mmol) in THF (2.1 mL) at 0 °C. The mixture 
was stirred for 10 min at room temperature before MeI (0.31 mL, 
4.9 mmol) was carefully added at 0 °C. Stirring was continued for 1 h at 
room temperature before water (0.5 mL) and tert-butyl methyl ether (10 mL) were introduced and the 
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layers were separated. The aqueous phase was extracted with tert-butyl methyl ether (2 x 30 mL) and 
the combined organic layers were washed with brine and dried over MgSO4. The solvent was evaporated 
and the crude product purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 10:1 – 5:1) to yield 
the title compound as a colorless oil (126 mg, 80%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.71 (m, 2H), 7.32 
– 7.27 (m, 2H), 5.11 (tdq, J = 7.1, 2.8, 1.4 Hz, 1H), 4.10 (t, J = 1.9 Hz, 2H), 3.82 (t, J = 1.9 Hz, 2H), 3.80 (d, 
J = 7.3 Hz, 3H), 3.18 (s, 3H), 2.42 (s, 3H), 1.72 (d, J = 1.3 Hz, 3H), 1.66 (d, J = 1.3 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 143.4, 139.1, 136.3, 129.5, 128.0, 118.1, 81.2, 79.8, 59.7, 57.5, 44.2, 35.9, 26.0, 21.7, 
18.0. IR (film) ṽ 2975, 2926, 1598, 1343, 1090 cm-1. HRMS (ESI+) for C17H23NO3S [M+Na]
+: calcd: 344.1291, 
found: 344.1294. 
N-(5-((tert-Butyldimethylsilyl)oxy)-4-hydroxy-4-methylpent-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-
1-yl)benzenesulfonamide (S52). n-BuLi (1.6 M in hexanes, 1.46 mL, 
2.34 mmol) was slowly added to a solution of alkyne S26 (500 mg, 
1.80 mmol) in THF (19.0 mL) at 0 °C. The solution was stirred for 
20 min at 0 °C before ketone S17 (509 mg, 2.7 mmol) was 
introduced. The mixture was warmed to room temperature and stirred for 5 min before sat. NH4Cl 
solution (10 mL) and EtOAc (50 mL) were added. The aqueous phase was extracted with EtOAc (2 x 
50 mL) and the combined organic layers were washed with brine and dried over MgSO4. The solvent was 
evaporated and the residue purified by flash chromatography (silica, hexanes/EtOAc 10:1 – 6:1 – 4:1) to 
yield the title compound as a colorless oil (503 mg, 60%). 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.70 (m, 2H), 
7.32 – 7.27 (m, 2H), 5.11 (tdq, J = 7.2, 2.9, 1.4 Hz, 1H), 4.09 (s, 2H), 3.81 (d, J = 7.3 Hz, 2H), 3.40 (d, 
J = 9.5 Hz, 1H), 3.29 (d, J = 9.4 Hz, 1H), 2.51 (br, 1H), 2.42 (s, 3H), 1.72 (d, J = 1.3 Hz, 3H), 1.68 (d, 
J = 1.3 Hz, 3H), 1.15 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 143.4, 139.0, 136.6, 
129.6, 128.0, 118.2, 87.7, 76.5, 70.8, 67.8, 44.0, 35.8, 26.0, 26.0, 25.2, 21.7, 18.5, 18.1, -5.2, -5.3. IR (film) 
ṽ 3513 (br), 2929, 2858, 1347, 1160, 1093 cm-1. HRMS (ESI+) for C24H39NO4SSi [M+Na]
+: calcd: 488.2261, 
found: 488.2264. 
N-(4,5-bis((tert-Butyldimethylsilyl)oxy)-4-methylpent-2-yn-1-yl)-4-methyl-N-(3-methylbut-2-en-1-
yl)benzenesulfonamide (S53). TBSOTf (0.15 mL, 0.64 mmol) was added to a solution of alcohol S52 
(250 mg, 0.0.54 mmol) and 2,6-lutidine (0.13 mL, 1.07 mmol) in 
CH2Cl2 (2.1 mL) at −78 °C. The mixture was allowed to reach room 
temperature and was stirred for 2 h before sat. NH4Cl solution 
(0.5 mL) was added. The layers were separated and the aqueous 
phase was extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were washed with brine and 
dried over MgSO4. The solvent was evaporated and the residue purified by flash chromatography (silica, 
hexanes/EtOAc 1:0 – 20:1) to yield the title compound as a light yellow oil (281 mg, 90%). 1H NMR 
(400 MHz, CDCl3) δ 7.75 – 7.70 (m, 2H), 7.30 – 7.26 (m, 2H), 5.12 (tdq, J = 7.2, 2.9, 1.3 Hz, 1H), 4.10 (s, 
2H), 3.82 (d, J = 7.2 Hz, 2H), 3.29 (s, 2H), 2.41 (s, 3H), 1.71 (d, J = 1.3 Hz, 3H), 1.68 (d, J = 1.3 Hz, 3H), 1.18 
(s, 3H), 0.87 (s, 9H), 0.82 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H), 0.02 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 143.2, 
138.7, 136.9, 129.6, 127.8, 118.3, 88.5, 77.4, 71.6, 70.0, 44.0, 35.9, 27.2, 26.0, 26.0, 25.8, 21.7, 18.5, 
18.1, -2.7, -2.9, -5.2. IR (film) ṽ 2929, 2857, 1351, 1162, 1112 cm-1. HRMS (ESI+) for C30H53NO4SSi2 
[M+Na]+: calcd: 602.3126, found: 602.3128. 
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4-Methyl-N-(3-methylbut-2-en-1-yl)-N-(4-oxopent-2-yn-1-yl)benzenesulfonamide (S54). n-BuLi (1.6 M in 
hexanes, 1.46 mL, 2.34 mmol) was slowly added to a solution of alkyne S26 
(500 mg, 1.80 mmol) in THF (19.0 mL) at 0 °C. The solution was stirred for 
20 min at 0 °C before N-methoxy-N-methylacetamide (0.29 mL, 2.7 mmol) 
was introduced. After reaching room temperature, the mixture was stirred 
for 5 min before sat. NH4Cl solution (10 mL) and EtOAc (50 mL) were added. The layers were separated 
and the aqueous phase was extracted with EtOAc (2 x 50 mL) and the combined organic layers were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography (silica, hexanes/EtOAc 10:1 – 6:1 – 4:1) to yield the 
title compound as a yellow oil (248 mg, 43%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.71 (m, 2H), 7.36 – 7.29 
(m, 2H), 5.10 (tdq, J = 7.1, 2.8, 1.4 Hz, 1H), 4.21 (s, 2H), 3.82 (d, J = 7.3 Hz, 2H), 2.42 (s, 3H), 2.08 (s, 3H), 
1.73 (d, J = 1.3 Hz, 3H), 1.66 (d, J = 1.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 183.3, 144.0, 139.9, 135.8, 
129.8, 127.9, 117.6, 84.9, 84.6, 44.6, 35.7, 32.4, 26.0, 21.7, 18.0. IR (film) ṽ 2974, 2921, 2209, 1679, 1348, 
1162 cm-1. HRMS (ESI+) for C17H21NO3S [M+Na]
+: calcd: 342.1134, found: 342.1135. 
4-Methyl-N-(3-(2-methyl-1,3-dioxolan-2-yl)prop-2-yn-1-yl)-N-(3-methylbut-2-en-1-yl)benzenesulfon-
amide (S55). p-TsOH ∙ H2O (7.4 mg, 0.04 mmol) was added to a vigorously stirred suspension of ynone 
S54 (125 mg, 0.39 mmol) and triethylorthoformate (70 mg, 0.47 mmol) in 
ethylene glycol (1.9 mL). The mixture was stirred at room temperature for 
24 h before solid NaHCO3 (30 mg) and sat. NaHCO3 solution (1 mL) were 
added. The mixture was diluted with EtOAc (20 mL) and water (5 mL), the 
layers were separated, the aqueous phase was extracted with EtOAc (2 x 30 mL) and the combined 
organic layers were washed with brine and dried over MgSO4. The solvent was evaporated and the 
residue purified by flash chromatography (silica, hexanes/EtOAc 10:1 – 6:1 – 4:1) to give the title 
compound as a colorless amorphous solid (116 mg, 82%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.71 (m, 
2H), 7.34 – 7.29 (m, 2H), 5.10 (tdq, J = 7.2, 2.9, 1.4 Hz, 1H), 4.11 (s, 2H), 3.91 – 3.83 (m, 2H), 3.82 – 3.77 
(m, 4H), 2.42 (s, 3H), 1.72 (d, J = 1.2 Hz, 3H), 1.67 (d, J = 1.3 Hz, 3H), 1.43 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 143.5, 139.1, 136.3, 129.7, 127.8, 118.1, 100.5, 83.9, 76.3, 64.6, 44.2, 35.6, 26.2, 26.0, 21.7, 
18.0. IR (film) ṽ 2973, 2895, 1347, 1185, 1161 cm-1. HRMS (ESI+) for C19H25NO4S [M+Na]
+: calcd: 386.1397, 
found: 386.1399. 
2-Methylnon-8-en-3-yn-2-ol (S56). n-BuLi (1.6 M in hexanes, 19.3 mL, 30.1 mmol) was added at 0 °C to a 
solution of 2-methyl-3-butin-2-ol (1.50 mL, 15.5 mmol) in THF (45 mL) and 
HMPA (18 mL). After 1 h at 0 °C, the reaction mixture was cooled to −78 °C and 
5-bromo-1-pentene (1.53 mL, 12.9 mmol) was slowly introduced. The mixture 
was warmed to room temperature during 1 h and then stirred at 70 °C for 
another 18 h. The mixture was cooled to room temperature and the reaction quenched with sat. NH4Cl 
solution (50 mL). The aqueous phase was extracted with Et2O (3 x 40 mL) and the combined organic 
layers were washed with sat. NaCl solution, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatography (silica, hexanes/EtOAc 5:1) to give the title 
compound as a colorless oil (1.54 g, 78%) 1H NMR (400 MHz, CDCl3) δ 5.79 (ddt, J = 17.0, 10.2, 6.7 Hz, 
1H), 5.08 – 4.95 (m, 2H), 2.19 (t, J = 7.1 Hz, 2H), 2.17 – 2.10 (m, 2H), 1.86 (s, 1H), 1.63 – 1.55 (m, 1H), 1.50 
S39 
 
(s, 6H).13C NMR (101 MHz, CDCl3) δ 137.9, 115.1, 85.4, 82.2, 65.3, 32.8, 31.7, 27.8, 18.0. IR (film) ṽ 3331, 
2980, 2933, 1641, 1439, 1364, 1240, 1163, 1133, 1083, 950, 912, 838 cm-1. HRMS (ESI+) for C10H16O 
[M+Na]+: calcd: 175.1093, found: 175.1094. 
tert-Butyldimethyl((2-methylnon-8-en-3-yn-2-yl)oxy)silane (S57). 2,6-Lutidine (0.4 mL, 3.4 mmol) and 
TBSOTf (0.47 mL, 2.0 mmol) were added at −15 °C to a solution of alcohol 
S56 (260 mg, 1.7 mmol) in CH2Cl2 (8 mL).The mixture was warmed to ambient 
temperature over the course of 2 h and stirring was continued for 14 h. The 
reaction was quenched with sat. NH4Cl solution (5 mL), the aqueous phase 
was extracted with CH2Cl2 (3 x 5 mL) and the combined organic layers were washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash 
chromatography (silica, hexanes/EtOAc 100:1) to give the title compound as a colorless oil (349 mg, 
77%). 1H NMR (400 MHz, CDCl3): δ 5.65 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 4.88 (ddd, J = 17.1, 1.7, 1.7 Hz, 
1H), 4.85 – 4.80 (m, 1H), 2.08 – 1.93 (m, 5H), 1.50 – 1.37 (m, 2H), 1.27 (s, 6H), 0.71 (s, 9H), 0.00 (s, 
6H).13C NMR (101 MHz, CDCl3): δ 138.1, 115.2, 86.1, 82.5, 66.5, 33.4, 33.0, 28.0, 25.9, 25.9, 18.2, 18.1, -
2.8. IR (film) ṽ 2930, 1247, 1159, 1035, 834, 774 cm-1. HRMS (CI) for C16H30OSi [M+H]
+: calcd: 267.2137, 
found: 267.2139. 
8-(Methoxymethoxy)-8-methylnon-1-en-6-yne (S58). Hünig’s base (1.17 mL, 6.7 mmol) and MOMCl 
(0.26 mL, 3.37 mmol) were added at 0 °C to a solution of alcohol S56 
(171 mg, 1.12 mmol) in CH2Cl2 (5 mL). The mixture was warmed to ambient 
temperature over 2 h and stirring was continued for another 14 h. The 
reaction was quenched with sat. NH4Cl solution (5 mL), the aqueous phase 
was extracted with CH2Cl2 (3 x 5 mL) and the combined organic layers were washed with sat. NaCl 
solution, dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (silica, hexanes/EtOAc 97:3) to give the title compound as a colorless oil 
(156 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 5.78 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.06 – 4.95 (m, 2H), 4.89 
(s, 2H), 3.37 (s, 3H), 2.21 (t, J = 7.1 Hz, 2H), 2.18 – 2.11 (m, 2H), 1.64 – 1.56 (m, 2H), 1.48 (s, 6H). 13C NMR 
(101 MHz, CDCl3) δ 138.0, 115.3, 93.2, 85.1, 82.3, 71.4, 55.5, 32.9, 30.7, 28.0, 18.1. IR (film) ṽ 2934, 1256, 
1144, 1031, 1001, 917, 810 cm-1. HRMS (ESI+) for C12H20O2 [M+Na]
+: calcd: 219.1356, found: 219.1356. 
Trimethyl(2-(((2-methylnon-8-en-3-yn-2-yl)oxy)methoxy)ethyl)silane (S59). Hünig’s base (1.21 mL, 
6.9 mmol) and SEMCl (0.62 mL, 3.48 mmol) were added at 0 °C to a solution 
of alcohol S56 (176.9 mg, 1.16 mmol) in CH2Cl2(5 mL). The mixture was 
warmed to ambient temperature over 2 h and stirring was continued for 
another 14 h. The reaction was quenched with sat. NH4Cl solution (5 mL), the 
aqueous phase was extracted with CH2Cl2 (3 x 5 mL) and the combined organic layers were washed with 
sat. NaCl solution, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified 
by flash chromatography (silica, hexanes/EtOAc 100:1) to give the title compound as a colorless oil 
(311 mg, 95%). 1H NMR (400 MHz, CDCl3) δ 5.79 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H), 5.06 – 4.95 (m, 2H), 4.94 
(s, 2H), 3.71 – 3.59 (m, 2H), 2.21 (t, J = 7.1 Hz, 2H), 2.18 – 2.09 (m, 2H), 1.67 – 1.55 (m, 2H), 1.48 (s, 6H), 
0.99 – 0.89 (m, 2H), 0.01 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 139.2, 116.6, 92.7, 86.2, 83.7, 72.5, 66.6, 
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34.2, 31.9, 29.3, 19.6, 19.4, 0.0. IR (film) ṽ 2953, 1248, 1095, 1027, 919, 857, 834 cm-1. HRMS (ESI+) for 
C16H30O2Si [M+Na]
+: calcd: 305.1907, found: 305.1908. 
4-Methyl-4-((triethylsilyl)oxy)pent-2-yn-1-ol (S60). n-BuLi (1.6 M in hexanes, 1.57 mL, 2.5 mmol) was 
added at 0 °C to a solution of alkyne S22 (500 mg, 2.5mmol) in THF (10 mL). The 
mixture was stirred for 1 h at this temperature before powdered 
paraformaldehyde (90 mg, 3.0 mmol) was slowly introduced and stirring was 
continued overnight at ambient temperature. The reaction was quenched with sat. 
NH4Cl solution (10 mL). The aqueous phase was extracted with Et2O (3 x 40 mL) and the combined 
organic layers were washed with sat. NaCl solution, dried over Na2SO4 and concentrated under vacuum. 
The crude product was purified by flash chromatography (silica, hexanes/EtOAc 9:1) to give the title 
compound as a colorless oil (529 mg, 92%). 1H NMR (400 MHz, CDCl3) δ 4.28 (d, J = 6.2 Hz, 2H), 1.42 (t, 
J = 6.2 Hz, 1H), 0.97 (t, J = 7.9 Hz, 9H), 0.74 – 0.62 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 91.4, 80.4, 66.3, 
51.4, 33.1, 7.1, 6.2. IR (film) ṽ 3340, 2955, 2876, 1377, 1239, 1160, 1035, 1002, 724 cm-1. HRMS (ESI+) for 
C12H24O2Si [M+Na]
+: calcd: 251.1438, found: 251.1436. 
Triethyl((2-methyl-5-((2-methylallyl)oxy)pent-3-yn-2-yl)oxy)silane (S61). Alcohol S60 (150 mg, 
0.66 mmol) was added at 0 °C to a suspension of NaH (15.7 mg, 0.66 mmol) 
in THF (5 mL). The mixture was stirred for 1 h at 0 °C before 3-bromo-2-
methylpropene (0.13 mL, 1.3 mmol) was slowly introduced. The mixture was 
allowed to reach ambient temperature overnight. The reaction was 
quenched with sat. NH4Cl solution (5 mL), the aqueous phase was extracted with CH2Cl2 (3 x 3 mL) and 
the combined organic layers were washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. The residue was purified by flash chromatography (silica, hexanes/EtOAc 98:2) to give 
the title compound as a colorless oil (145.8 mg, 79%). 1H NMR (400 MHz, CDCl3) δ 4.99 (s, 1H), 4.92 (s, 
1H), 4.16 – 4.10 (m, 2H), 3.96 (s, 2H), 1.80 – 1.70 (m, 3H), 1.49 (d, J = 1.0 Hz, 6H), 0.96 (t, J = 7.8 Hz, 9H), 
0.67 (q, J = 7.9 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 141.7, 113.0, 91.7, 78.5, 73.6, 66.3, 57.5, 33.2, 19.7, 
7.1, 6.2. IR (film) ṽ 2954, 2876, 1458, 1359, 1239, 1161, 1035, 1004, 725 cm-1. HRMS (ESI+) for C16H30O2Si 
[M+Na]+: calcd: 305.1907, found: 305.1903. 
Triethyl((2-methyl-5-((3-methylbut-2-en-1-yl)oxy)pent-3-yn-2-yl)oxy)silane (S62). Alcohol S60 (150 mg, 
0.66 mmol) was added at 0 °C to a suspension of NaH (15.7 mg, 
0.66 mmol) in THF (5 mL). The mixture was stirred for 1 h at 0 °C before 1-
bromo-3-methyl-2-butene (0.15 mL, 1.3 mmol) was slowly introduced. The 
mixture was allowed to reach ambient temperature overnight. The 
reaction was quenched with sat. NH4Cl solution (5 mL), the aqueous phase was extracted with CH2Cl2 (3 x 
3 mL) and the combined organic layers were washed with sat. NaCl solution, dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by flash chromatography (silica, 
hexanes/EtOAc 50:1) to give the title compound as a colorless oil (126 mg, 65%). 1H NMR (400 MHz, 
CDCl3) δ 5.40 – 5.26 (m, 1H), 4.14 (s, 2H), 4.03 (d, J = 6.7 Hz, 2H), 1.81 – 1.67 (m, 6H), 1.48 (s, 6H), 0.96 (t, 
J = 7.9 Hz, 9H), 0.66 (q, J = 7.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 138.2, 120.6, 91.6, 78.7, 66.3, 66.0, 
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57.4, 33.2, 26.0, 18.1, 7.1, 6.2. IR (film) ṽ 2956, 1716, 1362, 1237, 1163, 1037, 1004, 726 cm-1. HRMS 
(ESI+) for C17H32O2Si [M+Na]
+: calcd: 319.2064, found: 319.2063. 
((5-(Allyloxy)-2-methylpent-3-yn-2-yl)oxy)(tert-butyl)dimethylsilane (S63). To a solution of allyl 
propargyl ether (150 mg, 1.5 mmol)[30] in THF (6 mL) was added n-BuLi (1.6 M 
in hexanes, 0.97 mL, 1.56 mmol) at −78 °C. The mixture was stirred for 1 h at 
this temperature before acetone (0.17 mL, 2.3 mmol) was slowly introduced. 
The mixture was allowed to reach ambient temperature overnight. The 
reaction was quenched with sat. NH4Cl solution (10 mL). The aqueous phase was extracted with Et2O (3 x 
10 mL) and the combined organic layers were washed with sat. NaCl solution, dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was used directly for the next step.  
2,6-Lutidine (0.2 mL, 1.74 mmol) and TBSOTf (0.24 mL, 1 mmol) were added at −15 °C to a solution of the 
crude alcohol (134 mg, 0.89 mmol) in CH2Cl2 (2.5 mL). The mixture was warmed to ambient temperature 
over 2 h and stirring was continued for another 14 h. The reaction was quenched with sat. NH4Cl solution 
(5 mL), the aqueous phase was extracted with CH2Cl2 (3 x 3 mL) and the combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash chromatography (silica, hexanes/EtOAc 99:1) to give the title compound as a colorless 
oil (220 mg, 94%). 1H NMR (400 MHz, CDCl3) δ 5.91 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.31 (ddd, J = 17.2, 
1.6, 1.6 Hz, 1H), 5.22 (ddd, J = 10.4, 1.4, 1.3 Hz, 1H), 4.17 (s, 2H), 4.05 (dt, J = 5.8, 1.4 Hz, 2H), 1.46 (s, 6H), 
0.86 (s, 9H), 0.16 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 134.2, 117.9, 91.9, 78.4, 70.6, 66.4, 57.6, 33.0, 
25.8, 18.1, -2.8. IR (film) ṽ 2930, 1721, 1360, 1248, 1162, 1035, 828, 775, 678 cm-1. HRMS (ESI+) for 
C15H28O2Si [M+H]
+: calcd: 269.1931, found: 269.1933. 
3-(1-Methoxycyclohexyl)prop-2-yn-1-ol (S64). n-BuLi (1.6 M in hexanes, 2.94 mL, 4.7 mmol) was slowly 
added to a solution of alkyne S19 (500 mg, 3.6 mmol) in THF (38 mL) at 0 °C. The 
mixture was stirred for 30 min at 0 °C before powdered paraformaldehyde 
(141 mg, 4.7 mmol) was introduced. After stirring at room temperature for 18 h 
the reaction was quenched with water (10 mL) and EtOAc (50 mL). The layers 
were separated and the aqueous phase was extracted with EtOAc (2 x 50 mL). The combined organic 
layers were dried over MgSO4 and the solvent was removed under reduced pressure. The crude product 
was purified by flash chromatography (silica, hexanes/EtOAc 10:1 – 4:1) to yield the title compound as a 
colorless oil (371 mg, 61%). 1H NMR (400 MHz, CDCl3) δ 4.33 (s, 2H), 3.35 (s, 3H), 1.92 – 1.83 (m, 2H), 
1.70 – 1.44 (m, 8H), 1.37 – 1.23 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 87.0, 84.1, 73.9, 51.3, 50.8, 36.7, 
25.5, 22.8. IR (film) ṽ 3423 (br), 2935, 2858, 1448, 1077 cm-1. HRMS (ESI+) for C10H16O2 [M+Na]
+: calcd: 
191.1042, found: 191.1042. 
1-Methoxy-1-(3-((3-methylbut-2-en-1-yl)oxy)prop-1-yn-1-yl)cyclohexane (S65). A solution of alcohol 
S64 (360 mg, 2.1 mmol) in THF (1 mL) was added to a stirred 
suspension of NaH (87 mg, 3.6 mmol) in THF (13.9 mL) at 0 °C. The 
mixture was stirred for 10 min at room temperature before 1-bromo-3-
methyl-2-butene (0.30 mL, 2.6 mmol) was added. After stirring for 1 h 
at room temperature, the reaction was quenched with sat. NH4Cl solution (2 mL), water (4 mL) and tert-
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butyl methyl ether (30 mL). The aqueous phase was extracted with tert-butyl methyl ether (2 x 50 mL) 
and the combined organic layers were washed with brine and dried over MgSO4. The solvent was 
removed under reduced pressure and the crude product was purified by flash chromatography (silica, 
hexanes/EtOAc 40:1 – 20:1) to give the title compound as a colorless oil (266 mg, 53%). 1H NMR 
(400 MHz, CDCl3) δ 5.35 (tdq, J = 7.1, 2.8, 1.4 Hz, 1H), 4.20 (s, 2H), 4.06 (d, J = 7.1 Hz, 2H), 3.36 (s, 3H), 
1.94 – 1.82 (m, 2H), 1.76 (s, 3H), 1.70 (s, 3H), 1.69 – 1.45 (m, 7H), 1.37 – 1.23 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 138.4, 120.5, 87.3, 82.2, 74.1, 65.9, 57.28, 50.9, 36.8, 26.0, 25.6, 22.9, 18.2. IR (film) ṽ 2933, 
2856, 1674, 1446, 1073 cm-1. HRMS (ESI+) for C15H24O2 [M+Na]
+: calcd: 259.1668, found: 259.1669. 
Dimethyl 2-(3-(1-hydroxycyclohexyl)prop-2-yn-1-yl)-2-(3-methylbut-2-en-1-yl)malonate (S66). LiHMDS 
(1 M in THF, 1.0 mL, 1.0 mmol) was slowly added to a solution of alkyne 
S27 (200 mg, 0.84 mmol) in THF (8.2 mL) at −78 °C and the resulting 
mixture was stirred for 30 min at that temperature. Cyclohexanone 
(0.13 mL, 1.26 mmol) was slowly added at −78 °C and the resulting 
mixture warmed to room temperature. After 5 min, sat. NH4Cl solution (1 mL) and EtOAc (20 mL) were 
added and the layers were separated. The aqueous phase was extracted with EtOAc (3 x 30 mL) and the 
combined organic layers were washed with brine and dried over MgSO4. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 
10:1 – 5:1) to give the title compound as a colorless oil (189 mg, 67%). 1H NMR (400 MHz, CDCl3) δ 4.90 
(tp, J = 7.7, 1.5 Hz, 1H), 3.72 (s, 6H), 2.79 (s, 2H), 2.76 (d, J = 7.7 Hz, 2H), 1.87 – 1.72 (m, 5H), 1.70 (d, 
J = 1.4 Hz, 3H), 1.65 (d, J = 1.4 Hz, 3H), 1.58 – 1.44 (m, 5H), 1.23 – 1.13 (m, 1H). 13C NMR (101 MHz, CDCl3) 
δ 170.7, 136.9, 117.2, 87.1, 79.6, 68.9, 57.6, 52.8, 40.2, 31.0, 26.2, 25.3, 23.5, 22.9, 18.1. IR (film) ṽ 3468 
(br), 2933, 2858, 1732, 1437 cm-1. HRMS (ESI+) for C19H28O5 [M+Na]
+: calcd: 359.1829, found: 359.1829. 
Dimethyl 2-(3-(1-methoxycyclohexyl)prop-2-yn-1-yl)-2-(3-methylbut-2-en-1-yl)malonate (S67). A 
solution of alcohol S66 (180 mg, 0.54 mmol) in THF (1 mL) was slowly 
added to a suspension of NaH (64 mg, 2.7 mmol) in THF (2.2 mL) at 
0 °C. The mixture was stirred for 10 min at room temperature before 
MeI (0.34 mL, 5.4 mmol) was carefully added at 0 °C. After stirring for 
1 h at room temperature, water (0.5 mL) and tert-butyl methyl ether (10 mL) were introduced and the 
layers were separated. The aqueous phase was extracted with tert-butyl methyl ether (2 x 30 mL) and 
the combined organic layers were washed with brine and dried over MgSO4. The solvent was evaporated 
and the residue was purified by flash chromatography (silica, hexanes/EtOAc 40:1 – 20:1 – 15:1) to yield 
the title compound as a colorless oil (84 mg, 45%). 1H NMR (400 MHz, CDCl3) δ 4.91 (dddd, J = 9.2, 5.9, 
2.9, 1.5 Hz, 1H), 3.72 (s, 6H), 3.31 (s, 3H), 2.83 (s, 2H), 2.77 (d, J = 7.8 Hz, 2H), 1.88 – 1.77 (m, 2H), 1.70 (d, 
J = 1.3 Hz, 3H), 1.65 (d, J = 1.3 Hz, 3H), 1.64 – 1.41 (m, 8H), 1.31 – 1.23 (m, 2H). 13C NMR (101 MHz, CDCl3) 
δ 170.7, 136.9, 117.3, 84.2, 81.2, 74.1, 57.6, 52.8, 50.7, 37.0, 31.0, 26.2, 25.6, 23.0, 22.9, 18.1. IR (film) ṽ 
2935, 2857, 1738, 1437, 1224 cm-1. HRMS (ESI+) for C20H30O5 [M+Na]
+: calcd: 373.1985, found: 373.1983. 
Dimethyl 2-(4-methylpent-3-en-1-yl)-2-(prop-2-yn-1-yl)malonate (S68). Cs2CO3 (3.4 g, 10.5 mmol) and 
5-bromo-2-methyl-2-pentene (1.40 mL, 10.5 mmol) were added to a solution 
of malonate S21 (594 mg, 3.5 mmol) in acetone (23.1 mL). The mixture was 
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stirred at reflux temperature for 18 h before it was cooled to room temperature and diluted with tert-
butyl methyl ether (40 mL). The mixture was filtered through a pad of Celite and the filter cake was 
washed with tert-butyl methyl ether (100 mL). The combined filtrates were evaporated and the residue 
was purified by flash chromatography (silica, hexanes/tert-butyl methyl ether 40:1 – 20:1 – 15:1 – 10:1) 
to give the title compound as a colorless oil (740 mg, 84%). 1H NMR (400 MHz, CDCl3) δ 5.09 (tdq, J = 6.9, 
2.6, 1.3 Hz, 1H), 3.73 (s, 6H), 2.85 (d, J = 2.7 Hz, 2H), 2.12 – 2.06 (m, 2H), 2.00 (t, J = 2.7 Hz, 1H), 1.93 – 
1.85 (m, 2H), 1.67 (q, J = 1.3 Hz, 3H), 1.58 (d, J = 1.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.8, 133.0, 
122.9, 79.0, 71.4, 56.8, 52.9, 32.2, 25.8, 23.0, 22.9, 17.7. The spectral data is consistent with previously 
reported values.[31] 
Dimethyl 2-(3-(1-hydroxycyclohexyl)prop-2-yn-1-yl)-2-(4-methylpent-3-en-1-yl)malonate (S69). LiHMDS 
(1 M in THF, 1.9 mL, 1.9 mmol) was slowly added to a solution of 
alkyne S68 (400 mg, 1.59 mmol) in THF (15.4 mL) at −78 °C and the 
resulting mixture was stirred for 30 min at this temperature. 
Cyclohexanone (0.25 mL, 2.38 mmol) was slowly added at −78 °C and 
the resulting mixture was warmed to room temperature. After 5 min, sat. NH4Cl solution (1 mL) and 
EtOAc (20 mL) were introduced and the layers were separated, the aqueous phase was extracted with 
EtOAc (3 x 30 mL) and the combined organic layers were washed with brine and dried over MgSO4. The 
solvent was evaporated and the residue purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 
10:1 – 5:1). The product was obtained as a colorless oil (351 mg, 63%). 1H NMR (400 MHz, CDCl3) δ 5.08 
(tdq, J = 7.1, 2.8, 1.4 Hz, 1H), 3.72 (s, 6H), 2.87 (s, 2H), 2.11 – 2.03 (m, 2H), 1.93 – 1.77 (m, 5H), 1.70 – 
1.63 (m, 5H), 1.58 (d, J = 1.4 Hz, 3H), 1.50 (qd, J = 10.6, 9.6, 3.2 Hz, 5H), 1.25 – 1.13 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 171.0, 132.9, 123.0, 87.1, 79.2, 68.9, 57.2, 52.8, 40.3, 32.3, 25.8, 25.3, 23.5, 23.2, 
22.9, 17.7. IR (film) ṽ 3498 (br), 2933, 2857, 1733, 1438, 1171 cm-1. HRMS (ESI+) for C20H30O5 [M+Na]
+: 
calcd: 373.1985, found: 373.1983. 
Dimethyl 2-(3-(1-methoxycyclohexyl)prop-2-yn-1-yl)-2-(4-methylpent-3-en-1-yl)malonate (17). A 
solution of alcohol S69 (340 mg, 0.97 mmol) in THF (1 mL) was slowly 
added to a suspension of NaH (70 mg, 2.9 mmol) in THF (3.9 mL) at 
0 °C. The mixture was stirred for 10 min at room temperature before 
MeI (0.31 mL, 4.9 mmol) was carefully added at 0 °C. Stirring was 
continued for 1 h at room temperature before water (1 mL) and tert-butyl methyl ether (20 mL) were 
introduced and the layers were separated. The aqueous phase was extracted with tert-butyl methyl 
ether (2 x 50 mL) and the combined organic layers were washed with brine and dried over MgSO4. The 
solvent was evaporated and the residue purified by flash chromatography (silica, hexanes/EtOAc 20:1 – 
10:1 – 5:1) to yield the title compound as a colorless oil (263 mg, 74%). 1H NMR (400 MHz, CDCl3) δ 5.08 
(tdq, J = 7.2, 2.9, 1.4 Hz, 1H), 3.72 (s, 6H), 3.31 (s, 3H), 2.90 (s, 2H), 2.12 – 2.00 (m, 2H), 1.93 – 1.78 (m, 
4H), 1.70 – 1.56 (m, 3H), 1.67 (q, J = 1.9 Hz, 3H), 1.58 (s, 3H), 1.55 – 1.40 (m, 6H), 1.30 – 1.18 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 171.0, 132.8, 123.0, 84.3, 80.9, 74.2, 57.2, 52.8, 50.7, 37.0, 32.3, 25.8, 25.6, 
23.2, 23.0, 22.9, 17.7. IR (film) ṽ 2934, 2857, 1735, 1436, 1167 cm-1. HRMS (ESI+) for C21H32O5 [M+Na]
+: 
calcd: 387.2142, found: 387.2142. 
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4-(Methoxymethoxy)-4-methyloct-1-en-5-yne (S70). Allylmagnesium chloride (2 M in THF, 0.59 mL, 
1.19 mmol) was added to a stirred solution of 3-hexyn-2-one (57.0 mg, 0.59 mmol) 
in THF (2 mL) at 0 °C. The mixture was warmed to room temperature and stirring 
was continued for 18 h before sat. NH4Cl solution (3 mL) and Et2O (5 mL) were 
introduced. The layers were separated and the aqueous phase was extracted with Et2O (2 x 10 mL). The 
combined organic layers were washed with brine and dried over Na2SO4. The solvent was removed under 
reduced pressure and the residue was directly used in the next step without further purification. 
Hünig’s base (0.54 mL, 3.1 mmol) and MOMCl (0.12 mL, 1.6 mmol) were added at 0 °C to a solution of 
the crude alcohol (82 mg, 0.59 mmol) in CH2Cl2 (2.1 mL). The mixture was warmed to ambient 
temperature over 2 h and stirring was continued for another 14 h. The reaction was quenched with sat. 
NH4Cl solution (5 mL), the aqueous phase was extracted with CH2Cl2 (3 x 5 mL) and the combined organic 
layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by flash chromatography (silica, hexanes/EtOAc 98:2) to give the title compound as 
a colorless oil (67 mg, 62% over two steps). 1H NMR (400 MHz, CDCl3) δ6.01 – 5.81 (m, 1H), 5.14 – 5.07 
(m, 2H), 4.98 (d, J = 7.0 Hz, 1H), 4.85 (d, J = 7.0 Hz, 1H), 3.38 (s, 3H), 2.56 – 2.48 (m, 1H), 2.45 – 2.37 (m, 
1H), 2.23 (q, J = 7.5 Hz, 2H), 1.43 (s, 3H), 1.14 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 134.1, 117.9, 
93.2, 88.6, 74.0, 55.7, 47.6, 28.1, 14.1, 12.5, 1.2. IR (film) ṽ 2979, 1320, 1143, 1092, 1024, 917 cm-1. 
HRMS (ESI+) for C11H18O2 [M+Na]
+: calcd: 205.1199, found: 205.1201. 
1-((tert-Butyldimethylsilyl)oxy)-3-methyltridec-4-yn-3-ol (S71). n-BuLi (1.6 M in hexanes, 7.04 mL, 
11.3 mmol) was slowly added to a solution of 1-decyne (2.03 mL, 11.3 mmol) in 
THF (100 mL) at 0 °C. The solution was stirred for 20 min at 0 °C before ketone 
S18 (1.9 g, 9.4 mmol) was introduced. After stirring at room temperature for 
20 min, aq. sat. NH4Cl (10 mL) and tert-butyl methyl ether (100 mL) were added. 
The layers were separated and the aqueous phase was extracted with tert-butyl 
methyl ether (2 x 100 mL). The combined organic layers were washed with brine and dried over MgSO4. 
The solvent was evaporated and the crude product was purified by flash chromatography (silica, 
hexanes/EtOAc 1:0 – 20:1) to yield the title compound as a colorless oil (2.65 g, 83%). 1H NMR (400 MHz, 
CDCl3) δ 4.53 (br, 1H), 4.23 (ddd, J = 10.8, 10.0, 3.1 Hz, 1H), 3.87 (ddd, J = 10.1, 4.5, 3.4 Hz, 1H), 2.20 (t, 
J = 7.1 Hz, 2H), 1.95 (ddd, J = 14.1, 10.8, 4.5 Hz, 1H), 1.69 (dt, J = 14.1, 3.2 Hz, 1H), 1.56 – 1.45 (m, 2H), 
1.46 (s, 3H), 1.42 – 1.33 (m, 2H), 1.33 – 1.22 (m, 8H), 0.91 (s, 9H), 0.88 (t, J = 7.1 Hz, 3H), 0.11 (s, 3H), 0.09 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 84.1, 83.5, 68.8, 62.1, 43.6, 32.0, 30.9, 29.4, 29.3, 29.1, 29.0, 26.0, 
22.8, 18.9, 18.3, 14.3, -5.4, -5.5. IR (film) ṽ 3503 (br), 2954, 2928, 2856, 1255, 1093 cm-1. HRMS (ESI+) for 
C20H40O2Si [M+Na]
+: calcd: 363.2690, found: 363.2691. 
tert-Butyl((3-methoxy-3-methyltridec-4-yn-1-yl)oxy)dimethylsilane (S72). A solution of alcohol S71 
(1.8 g, 5.3 mmol) in THF (5 mL) was added to a stirred suspension of NaH 
(317 mg, 13.2 mmol) in THF (23 mL) at 0 °C. The mixture was stirred for 10 min 
at room temperature before MeI (1.66 mL, 26.4 mmol) was added. After stirring 
for 1 h at room temperature sat. NH4Cl solution (10 mL), water (10 mL) and tert-
butyl methyl ether (60 mL) were added to the mixture and the layers were 
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separated. The aqueous phase was extracted with tert-butyl methyl ether (2 x 100 mL) and the combined 
organic layers were washed with brine and dried over MgSO4. The solvent was evaporated and the crude 
product purified by flash chromatography (silica, hexanes/EtOAc 1:0 – 20:1) to give the title compound 
as a colorless oil (1.77 g, 94%). 1H NMR (400 MHz, CDCl3) δ 3.80 (ddd, J = 7.9, 6.6, 1.1 Hz, 2H), 3.31 (s, 
3H), 2.20 (t, J = 7.0 Hz, 2H), 1.99 – 1.84 (m, 2H), 1.54 – 1.46 (m, 2H), 1.42 – 1.34 (m, 2H), 1.39 (s, 3H), 1.34 
– 1.21 (m, 8H), 0.89 (s, 9H), 0.88 (t, J = 7.0 Hz, 3H), 0.06 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 86.2, 80.8, 
72.5, 60.0, 51.2, 44.2, 32.0, 29.4, 29.2, 29.0, 28.9, 26.6, 26.1, 22.8, 18.8, 18.5, 14.3, -5.1, -5.1. IR (film) ṽ 
2955, 2928, 2856, 1463, 1254, 1079 cm-1. HRMS (ESI+) for C21H42O2Si [M+Na]
+: calcd: 377.2846, found: 
377.2846. 
3-Methoxy-3-methyltridec-4-yn-1-ol (S73). TBAF (1 M in THF) was added to a solution of silyl ether S72 
(1.77 g, 4.98 mmol) in THF (32 mL) at room temperature. The mixture was stirred 
for 1 h before sat. NH4Cl solution (5 mL), water (5 mL) and EtOAc (30 mL) were 
added. The aqueous phase was extracted with EtOAc (2 x 80 mL) and the 
combined organic layers were washed with brine and dried over MgSO4. The 
solvent was evaporated and the residue was purified by flash chromatography 
(silica, hexanes/EtOAc 10:1 – 4:1) to give the title compound as a colorless oil (1.03 g, 86%). 1H NMR 
(400 MHz, CDCl3) δ 3.98 (ddd, J = 11.6, 8.3, 3.5 Hz, 1H), 3.76 (ddd, J = 11.3, 6.0, 3.8 Hz, 1H), 3.34 (s, 3H), 
2.74 (br, 1H), 2.21 (t, J = 7.1 Hz, 2H), 1.97 (ddd, J = 14.4, 8.3, 3.9 Hz, 1H), 1.86 (ddd, J = 14.4, 6.0, 3.5 Hz, 
1H), 1.56 – 1.46 (m, 2H), 1.42 (s, 3H), 1.38 (m, 2H), 1.33 – 1.22 (m, 8H), 0.88 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 87.3, 80.2, 75.0, 60.4, 51.3, 44.1, 32.0, 29.3, 29.2, 29.0, 28.9, 26.1, 22.8, 18.7, 14.3. IR 
(film) ṽ 3424 (br), 2927, 2856, 1464, 1078 cm-1. HRMS (ESI+) for C15H28O2 [M+Na]
+: calcd: 263.1981, 
found: 263.1981. 
3-Methoxy-3-methyltridec-4-ynal (S74). NaHCO3 (874 mg, 10.4 mmol) and Dess-Martin periodinane 
(1.06 g, 2.5 mmol) were added to a solution of alcohol S73 (500 mg, 2.08 mmol) in 
wet CH2Cl2 (19 mL) at 0 °C. The mixture was stirred at room temperature for 30 min 
before sat. Na2S2O3 solution (7 mL) and water (4 mL) were introduced. The layers 
were separated, the aqueous phase was extracted with CH2Cl2 (2 x 60 mL) and the 
combined organic layers were washed with brine and dried over MgSO4. The solvent 
was evaporated and the residue purified by flash chromatography (silica, hexanes/EtOAc 10:1). The 
product was obtained as a colorless oil (421 mg, 85%). 1H NMR (400 MHz, CDCl3) δ 9.85 (t, J = 2.9 Hz, 1H), 
3.37 (s, 3H), 2.64 (dd, J = 15.3, 3.0 Hz, 1H), 2.58 (dd, J = 15.3, 2.8 Hz, 1H), 2.22 (t, J = 7.1 Hz, 2H), 1.51 (m, 
2H), 1.47 (s, 3H), 1.42 – 1.33 (m, 2H), 1.27 (m, 8H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 201.9, 88.4, 79.5, 70.9, 54.5, 51.6, 32.0, 29.3, 29.2, 29.0, 28.7, 26.5, 22.8, 18.7, 14.3. IR (film) ṽ 2928, 
2856, 1726, 1463, 1075 cm-1. HRMS (ESI+) for C15H26O2 [M+Na]
+: calcd: 261.1825, found: 261.1827. 
5-Methoxy-2,5-dimethylpentadec-2-en-6-yne (S75). n-BuLi (1.6 M in hexanes, 0.60 mL, 0.96 mmol) was 
slowly added to a stirred suspension of isopropyltriphenylphosphonium iodide 
(492 mg, 1.14 mmol) in THF (5.7 mL) at 0 °C. The mixture was stirred for 30 min at 
0 °C before a solution of aldehyde S74 (208 mg, 0.88 mmol) in THF (1.4 mL) was 
added. After stirring at 0 °C for 1 h, sat. NH4Cl solution (2 mL) and tert-butyl 
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methyl ether (10 mL) were introduced and the layers separated. The aqueous phase was extracted with 
tert-butyl methyl ether (2 x 30 mL) and the combined organic layers were dried over MgSO4. The solvent 
was evaported and the residue purified by flash chromatography (silica, hexanes/EtOAc 1:0 – 75:1 – 
50:1) to yield the title compound as a colorless oil (55 mg, 24%). 1H NMR (400 MHz, CDCl3) δ 5.24 (tdq, 
J = 7.2, 2.9, 1.4 Hz, 1H), 3.35 (s, 3H), 2.43 – 2.30 (m, 2H), 2.21 (t, J = 7.0 Hz, 2H), 1.74 (q, J = 1.3 Hz, 3H), 
1.63 (s, 3H), 1.55 – 1.46 (m, 2H), 1.43 – 1.36 (m, 2H), 1.34 (s, 3H), 1.32 – 1.23 (m, 8H), 0.91 – 0.86 (t, 
J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 134.2, 119.5, 85.9, 81.4, 74.0, 51.4, 39.8, 32.0, 29.4, 29.2, 
29.0, 26.2, 25.9, 22.8, 18.8, 18.3, 14.3. IR (film) ṽ 2928, 2857, 1458, 1367, 1089 cm-1. HRMS (ESI+) for 
C18H32O [M+H]
+: calcd: 265.2526, found: 265.2526. 
2,6-Dimethylhexadec-2-en-7-yn-6-ol (S76). n-BuLi (1.6 M in hexanes, 1.78 mL, 2.85 mmol) was added 
slowly to a solution of 1-decyne (0.51 mL, 2.85 mmol) in THF (25 mL) at 0 °C. 
The solution was stirred for 20 min at 0 °C before 6-methyl-5-hepten-2-one 
(300 mg, 2.38 mmol) was introduced. After stirring at room temperature for 
20 min, sat. NH4Cl solution (2 mL) and tert-butyl methyl ether (25 mL) were 
added, the layers were separated and the aqueous phase was extracted with 
tert-butyl methyl ether (2 x 25 mL). The combined organic layers were washed with brine and dried over 
MgSO4, the solvent was evaporated and the residue purified by flash chromatography (silica, 
hexanes/EtOAc 20:1 – 10:1) to yield the title compound as a colorless oil (546 mg, 87%). 1H NMR 
(400 MHz, CDCl3) δ 5.20 – 5.14 (m, 1H), 2.32 – 2.22 (m, 1H), 2.19 (t, J = 7.1 Hz, 2H), 1.85 (br, 1H), 1.69 (q, 
J = 1.3 Hz, 3H), 1.68 – 1.66 (m, 2H), 1.65 (d, J = 1.2 Hz, 3H), 1.54 – 1.46 (m, 2H), 1.45 (s, 3H), 1.42 – 1.33 
(m, 2H), 1.32 – 1.22 (m, 9H), 0.91 – 0.86 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 132.4, 124.2, 84.2, 84.0, 
68.7, 43.8, 32.0, 30.4, 29.3, 29.2, 29.0, 28.9, 25.9, 24.0, 22.8, 18.8, 17.8, 14.3. IR (film) ṽ 3384 (br), 2925, 
2856, 1455, 1375 cm-1. HRMS (ESI+) for C18H32O [M+Na]
+: calcd: 287.2345, found: 287.2345. 
6-Methoxy-2,6-dimethylhexadec-2-en-7-yne (S77). A solution of alcohol S76 (300 mg, 1.13 mmol) in THF 
(1 mL) was added to a stirred suspension of NaH (68 mg, 2.84 mmol) in THF 
(4.9 mL) at 0 °C. The mixture was stirred for 10 min at room temperature 
before MeI (0.36 mL, 5.67 mmol) was added and stirring continued for 1 h at 
room temperature. sat. NH4Cl solution (2 mL), water (2 mL) and tert-butyl 
methyl ether (20 mL) were introduced and the layers separated. The aqueous 
phase was extracted with tert-butyl methyl ether (2 x 30 mL) and the combined organic layers were 
washed with brine and dried over MgSO4. The solvent was evaporated and the residue purified by flash 
chromatography (silica, hexanes/EtOAc 1:0 – 20:1) to give the product as a colorless oil (284 mg, 90%). 
1H NMR (400 MHz, CDCl3) δ 5.13 (tdq, J = 7.2, 2.9, 1.4 Hz, 1H), 3.33 (s, 3H), 2.21 (t, J = 7.0 Hz, 2H), 2.17 – 
2.06 (m, 3H), 1.68 (q, J = 1.2 Hz, 3H), 1.67 – 1.58 (m, 2H), 1.62 (d, J = 1.2 Hz, 3H), 1.54 – 1.46 (m, 2H), 1.42 
– 1.35 (m, 2H), 1.37 (s, 3H), 1.33 – 1.23 (m, 8H), 0.91 – 0.86 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 131.8, 
124.3, 86.0, 81.2, 73.7, 51.3, 41.6, 32.0, 29.4, 29.2, 29.0, 29.0, 26.1, 25.9, 23.4, 22.8, 18.8, 17.8, 14.3. IR 
(film) ṽ 2926, 2856, 1459, 1173, 1088, 1073 cm-1. HRMS (ESI+) for C19H34O [M+H]




HYDROGENATIVE CYCLOPROPANATION AND METATHESIS REACTIONS 
Representative Procedure A. Preparation of cycloalkene 11a. [Cp*RuCl]4 (2.3 mg, 2 mol%) was added to 
a stirred solution of enyne 1f (24.8 mg, 0.11 mmol) in 1,2-dichloroethane (1 mL, 0.1 M) in a flame dried 
Schlenk tube under argon. H2 was bubbled through the mixture for 2 min before After stirring for 3 h at 
70 °C, the mixture was allowed to cool to room temperature, the solvent was removed under reduced 
pressure and the crude product was purified by flash chromatography (silica, pentane/Et2O 100:1) to 
yield the title product as colorless  oil (20.4 mg, 93%). 
Representative Procedure B. Preparation of cycloalkene 18. TBACl (0.021 M in 1,2-dichloroethane, 
0.42 mL, 11 mol%) was added to solid [Cp(Me2CO2Et)Ru(NCMe)3][PF6] 21 (4.3 mg, 10 mol%) in a flame 
dried Schlenk tube under argon. The mixture was stirred for 5 min at room temperature before enyne 17 
(29.3 mg, 0.08 mmol) in 1,2-dichloroethane (0.5 mL, 0.1 M) was added. H2 was bubbled through the 
mixture for 2 min before the flask was immersed into a pre-heated oil bath at 70 °C keeping a static H2 
atmosphere (ambient pressure, H2 filled balloon). After stirring for 3 h at 70 °C, the mixture was allowed 
to cool to room temperature and the solvent was removed under reduced pressure. The crude product 
was purified by flash chromatography (silica, hexanes/EtOAc 40:1 – 20:1 – 10:1) to yield the title product 
as light grey oil (16.9 mg, 65%). 
Representative Procedure C. Preparation of cyclopropane 4a. [Cp*RuCl]4 (2.6 mg, 2 mol%) was added to 
a stirred solution of enyne S57 (31.6 mg, 0.12 mmol) in CH2Cl2 (1.2 mL, 0.1 M) in a flame dried Schlenk 
tube under argon. H2 was bubbled through the mixture for 2 min and stirring was continued for 18h 
under H2 atmosphere (ambient pressure, H2 filled balloon). The solvent was removed under reduced 
pressure and the crude product was purified by flash chromatography (silica, hexanes/EtOAc 100:1) to 
yield the title product as colorless oil (29.1 mg, 91%). 
Representative Procedure D. Preparation of cyclopropane 3b. [Cp*RuCl]4 (3.5 mg, 2 mol%) was added 
to a stirred solution of enyne S30 (35.0 mg, 0.16 mmol) in 1,2-dichloroethane (1.6 mL, 0.1 M) in a flame 
dried Schlenk tube under argon. H2 was bubbled through the mixture for 2 min before before the flask 
was immersed into a pre-heated oil bath at 70 °C keeping a static H2 atmosphere (ambient pressure, H2 
filled balloon). After stirring was continued for 18 h at 70 °C, the mixture was allowed to cool to room 
temperature and the solvent was removed under reduced pressure. The crude product was purified by 
flash chromatography (silica, hexanes/EtOAc 50:1) to yield the title product as colorless oil (32.2 mg, 
91%). 
Representative Procedure E. Preparation of cyclopropane 4e. [Cp*RuCl]4 (1.0 mg, 2 mol%) was added to 
a stirred solution of enyne S43 (20.0 mg, 0.05 mmol) in 1,2-dichloroethane (1 mL, 0.5 M) in a flame dried 
thick-walled Schlenk tube under argon. H2 was bubbled through the mixture for 2 min before the tube 
was sealed and immersed into a pre-heated oil bath at 90 °C keeping a static H2 atmosphere. The mixture 
was stirred for 18 h at 90 °C before it was cooled to room temperature. The solvent was removed under 
reduced pressure and the crude product was purified by flash chromatography (silica, hexanes/EtOAc 




 (1S*,5R*)-1-((1-methoxycyclohexyl)methyl)bicyclo[3.1.0]hexane (3a). A detailed procedure for the 
preparation of this compound, a compilation of analytical and spectroscopic data 
as well as copies of the spectra are contained in the Supporting Information of our 
previous publication.[28] 
 (1S*,5R*)-1-((1-methoxycyclohexyl)methyl)-5-methylbicyclo[3.1.0]hexane [3.1.0]hexane (3b). 
According to the Representative Procedure A from enyne S30 (35.0 mg, 
0.16 mmol); colorless oil (32.2 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 3.15 (s, 3H), 
1.97 (dd, J = 12.4, 7.8 Hz, 1H), 1.87 – 1.70 (m, 3H), 1.71 – 1.62 (m, 1H), 1.62 – 1.51 
(m, 4H), 1.53 – 1.38 (m, 5H), 1.40 – 1.22 (m, 3H), 1.13 (d, J = 14.9 Hz, 1H), 1.08 (s, 3H), 0.53 (d, J = 4.8 Hz, 
1H), 0.04 (d, J = 4.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 76.7, 48.2, 38.8, 35.1, 34.5, 34.5, 34.2, 27.8, 
26.6, 26.2, 22.1, 22.1, 20.8, 19.2, 18.6. IR (film) ṽ 2928, 2851, 1445, 1081 cm-1. HRMS (ESI+) for C15H26O 
[M+H]+: calcd: 223.2056, found: 223.2055. 
 ((1-((1S*,5R*)-bicyclo[3.1.0]hexan-1-yl)-2-methylpropan-2-yl)oxy)(tert-butyl)dimethylsilane (4a). 
According to the Representative Procedure C from enyne S57 (31.6 mg, 0.12 mmol); 
colorless oil (29.1 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 1.92 (dd, J = 14.1, 1.4 Hz, 1H), 
1.81 (dd, J = 12.0, 7.8 Hz, 1H), 1.74 – 1.51 (m, 4H), 1.29 (d, J = 14.4 Hz, 1H), 1.27 (s, 
3H), 1.24 (s, 3H), 1.18 (d, J = 8.3 Hz, 1H), 0.87 – 0.86 (m, 1H), 0.86 (s, 9H), 0.44 – 0.31 (m, 2H), 0.08 (s, 
3H), 0.07 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 75.6, 52.2, 33.1, 30.9, 30.3, 27.0, 26.1, 26.0, 24.0, 22.3, 
18.2, 13.6, -1.7. IR (film) ṽ 2954, 2929, 2857, 1462, 1251, 1144, 1031, 832, 769, 689 cm-1. HRMS (CI) for 
C16H32OSi [M+H]
+: calcd: 269.2295, found: 269.2295. 
 (2-(((1-((1S*,5R*)-bicyclo[3.1.0]hexan-1-yl)-2-methylpropan-2-yl)oxy)methoxy)ethyl)trimethylsilane 
(4b). According to the Representative Procedure C from enyne S59 (27.6 mg, 
0.10 mmol); colorless oil (28.0 mg, quant.). 1H NMR (400 MHz, CDCl3) δ 4.77 – 4.71 
(m, 2H), 3.67 – 3.55 (m, 2H), 1.97 (d, J = 14.4 Hz, 1H), 1.85 – 1.76 (m, 1H), 1.70 – 1.48 
(m, 4H), 1.34 (d, J = 14.5 Hz, 1H), 1.28 (s, 3H), 1.24 (s, 3H), 1.18 – 1.07 (m, 1H), 0.97 – 0.82 (m, 3H), 0.43 – 
0.38 (m, 1H), 0.34 (dd, J = 7.9, 4.8 Hz, 1H), -0.00 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 89.3, 77.9, 64.9, 
48.6, 33.0, 27.3, 27.0, 25.7, 24.1, 22.3, 18.4, 13.6, -1.2. IR (film) ṽ 2955, 1259, 1091, 1023, 858, 833, 797, 
692 cm-1. HRMS (ESI+) for C16H32O2Si [M+Na]
+: calcd: 307.2064, found: 307.2066. 
 (1S*,5R*)-1-(2-(methoxymethoxy)-2-methylpropyl)bicyclo[3.1.0]hexane (4c). According to the 
Representative Procedure C from enyne S58 (34.3 mg, 0.17 mmol); colorless oil 
(27.4 mg, 79%). 1H NMR (400 MHz, CDCl3) δ 4.71 (q, J = 7.2 Hz, 2H), 3.36 (s, 3H), 2.00 
(dd, J = 14.4, 1.5 Hz, 1H), 1.86 – 1.78 (m, 1H), 1.73 – 1.48 (m, 5H), 1.35 (d, J = 14.4 Hz, 
1H), 1.29 (s, 3H), 1.26 (s, 3H), 1.22 – 1.08 (m, 1H), 0.87 (dt, J = 8.2, 4.1 Hz, 1H), 0.45 – 0.40 (m, 1H), 0.39 – 
0.32 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 91.1, 78.1, 55.2, 48.6, 33.0, 27.3, 27.0, 26.9, 25.6, 24.1, 22.3, 
13.6. IR (film) ṽ 2928, 1715, 1449, 1259, 1087, 1030, 919, 806 cm-1. HRMS (ESI+) for C12H22O2 [M+Na]
+: 




 (1R*,5R*)-1-(2-((tert-butyldimethylsilyl)oxy)-2-methylpropyl)-3-tosyl-3-azabicyclo[3.1.0]hexane (4e). 
According to the Representative Procedure E from enyne S43 (20.0 mg, 0.05 mmol); 
colorless solid (15.6 mg, 78%). Single crystals suitable for X-ray analysis were grown 
by slowly cooling a saturated solution of product in Et2O to −20 °C. m.p.: 104-105 °C. 
1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.3 Hz, 2H), 7.34 – 7.27 (m, 2H), 3.64 (d, 
J = 9.6 Hz, 1H), 3.47 (d, J = 9.0 Hz, 1H), 2.98 (dd, J = 9.0, 3.9 Hz, 1H), 2.91 (d, J = 9.9 Hz, 1H), 2.43 (s, 3H), 
1.96 (d, J = 14.2 Hz, 1H), 1.26 (s, 3H), 1.18 (s, 3H), 1.09 – 0.97 (m, 2H), 0.89 (s, 9H), 0.74 (t, J = 4.9 Hz, 1H), 
0.59 (dd, J = 7.9, 5.1 Hz, 1H), 0.10 (s, 3H), 0.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 143.3, 133.6, 129.6, 
127.8, 74.9, 54.3, 49.6, 49.2, 31.4, 28.8, 26.2, 25.0, 21.7, 21.2, 18.2, 15.2, -1.7, -1.7. IR (film) ṽ 2928, 2855, 
1462, 1347, 1163, 1132, 1027, 832, 771, 664, 567, 548 cm-1. HRMS (ESI+) for C22H37NO3SSi [M+Na]
+: calcd: 
446.2156, found: 446.2155. 
 ((1-((1R*,5R*)-3-oxabicyclo[3.1.0]hexan-1-yl)-2-methylpropan-2-yl)oxy)(tert-butyl)dimethylsilane (4f). 
According to the Representative Procedure E from enyne S63 (22.3 mg, 0.08 mmol), 
flash chromatography (silica, hexanes/EtOAc 97:3), colorless oil (12.7 mg, 56%). 
1H NMR (400 MHz, CDCl3) δ 3.90 (d, J = 8.5 Hz, 1H), 3.76 – 3.64 (m, 2H), 3.62 (d, 
J = 8.5 Hz, 1H), 2.13 (d, J = 14.2 Hz, 1H), 1.32 (d, J = 14.3 Hz, 1H), 1.28 (s, 3H), 1.24 (s, 3H), 1.20 (d, 
J = 12.1 Hz, 1H), 1.13 (td, J = 6.0, 2.8 Hz, 1H), 0.86 (s, 9H), 0.63 (d, J = 6.4 Hz, 2H), 0.10 (s, 3H), 0.08 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 75.0, 74.1, 69.0, 48.8, 31.2, 29.2, 26.1, 25.9, 22.9, 18.2, 14.7, -1.7. IR (film) ṽ 
2956, 2856, 1780, 1364, 1252, 1131, 1024, 830, 770, 690 cm-1. HRMS (ESI+) for C15H30O2Si [M+H]
+: calcd: 
271.2088, found: 271.2087. 
 triethyl((2-methyl-1-((1R*,5R*)-5-methyl-3-oxabicyclo[3.1.0]hexan-1-yl)propan-2-yl)oxy)silane (4g). 
According to the Representative Procedure E from enyne S61 (21.0 mg, 0.07 mmol); 
colorless oil (18.8 mg, 89%). 1H NMR (400 MHz, CDCl3) δ 3.96 (d, J = 8.7 Hz, 1H), 3.73 
(d, J = 7.9 Hz, 1H), 3.58 (d, J = 8.8 Hz, 1H), 3.42 (d, J = 8.0 Hz, 1H), 1.91 (d, J = 13.9 Hz, 
1H), 1.26 (s, 6H), 1.16 (d, J = 14.1 Hz, 1H), 1.09 (s, 3H), 0.95 (t, J = 7.9 Hz, 9H), 0.70 (d, J = 4.4 Hz, 1H), 0.58 
(q, J = 7.8 Hz, 6H), 0.33 (d, J = 4.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 75.1, 74.6, 74.1, 45.2, 31.5, 29.3, 
28.4, 25.8, 19.7, 13.6, 7.3, 6.9. IR (film) ṽ 2956, 2876, 1458, 1225, 1173, 1097, 1035, 925, 719 cm-1. HRMS 
(ESI+) for C16H32O2Si [M+Na]
+: calcd: 307.2064, found: 307.2064. 
 (1R*,5S*)-1-ethyl-3-(methoxymethoxy)-3-methylbicyclo[3.1.0]hexane (5). According to the 
Representative Procedure D (using additional [Cp*RuCl]4 (2 mol%) added after 12 h and 
stirring was continued for another 12 h) from enyne S70 (24.0 mg, 0.14 mmol); colorless 
oil (19.5 mg, 80%, mixture of diastereomers 1.3 : 1). 1H NMR (400 MHz, CDCl3) δ 4.74 – 
4.63 (m, 1H), 4.64 (s, 1H), 3.37 (s, 1.35H), 3.34 (s, 1.65H), 2.32 (dd, J = 13.9, 6.2 Hz, 0.55H), 
2.12 – 1.82 (m, 2H), 1.71 – 1.48 (m, 2.75H), 1.31 (s, 1.65H), 1.29 – 1.24 (m, 0.7H), 1.22 (s, 1.35H), 1.17 – 
1.09 (m, 0.45H); 1.04 – 0.94 (m, 55H), 0.94 – 0.85 (m, 3H), 0.84 – 0.78 (m, 0.55H), 0.59 – 0.52 (m, 0.45H), 
0.41 – 0.34 (m, 0.55H), 0.23 – 0.16 (m, 0.45H). 13C NMR (101 MHz, CDCl3) δ 92.0, 91.7, 89.4, 86.5, 55.5, 
55.3, 46.9, 45.3, 43.6, 42.0, 31.5, 30.2, 29.8, 29.4, 27.6, 27.0, 23.8, 22.9, 22.0, 17.5, 12.0, 11.9. IR (film) ṽ 
2959, 2626, 2727, 1461, 1259, 1074, 1019, 796 cm-1. HRMS (ESI+) for C11H20O2 [M+Na]




2-((1S*,6R*)-1-Methyl-3-tosyl-3-azabicyclo[4.1.0]heptan-6-yl)propan-2-ol (6). A detailed 
procedure for the preparation of this compound, a compilation of analytical and 
spectroscopic data as well as copies of the spectra are contained in the Supporting 
Information of our previous publication.[28] 
 
 (1R*,6R*)-6-((1-methoxycyclohexyl)methyl)-3-tosyl-3-azabicyclo[4.1.0]heptane (7). According to the 
Representative Procedure A from enyne S31 (35.0 mg, 0.09 mmol); colorless 
oil (27.2 mg, 77%). 1H NMR (400 MHz, CDCl3) δ 7.63 – 7.59 (m, 2H), 7.31 – 7.28 
(m, 2H), 3.31 (dt, J = 11.4, 1.4 Hz, 1H), 3.22 (dd, J = 11.6, 5.4 Hz, 1H), 3.08 (s, 
3H), 2.91 – 2.84 (m, 1H), 2.71 (ddd, J = 12.0, 8.2, 5.3 Hz, 1H), 2.42 (s, 3H), 2.12 
(dt, J = 13.7, 5.8 Hz, 1H), 1.92 (ddd, J = 13.8, 8.2, 5.3 Hz, 1H), 1.81 – 1.67 (m, 2H), 1.60 – 1.33 (m, 6H), 1.28 
– 1.08 (m, 4H), 0.82 (dtd, J = 8.8, 5.4, 1.9 Hz, 1H), 0.51 (dd, J = 8.7, 4.9 Hz, 1H), 0.42 (t, J = 5.2 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 143.4, 133.9, 129.7, 127.7, 76.7, 47.9, 45.0, 44.9, 42.9, 35.1, 34.9, 28.0, 26.0, 
21.9, 21.8, 21.7, 17.8, 17.2, 15.1. IR (film) ṽ 2929, 2854, 1455, 1339, 1160, 1075 cm-1. HRMS (ESI+) for 
C21H31NO3S [M+Na]
+: calcd: 400.1917, found: 400.1917. 
(1S*,6S*)-1-((1-Methoxycyclohexyl)methyl)bicyclo[4.1.0]heptan-2-one (8). A 
detailed procedure for the preparation of this compound, a compilation of 
analytical and spectroscopic data as well as copies of the spectra are contained in 
the Supporting Information of our previous publication.[28] 
(Z)-3-Methyl-4-(2-methylpropylidene)-1-tosylpyrrolidine (10a). According to the Representative 
Procedure A from enyne 9a (28.9 mg, 0.09 mmol); colorless solid (20.2 mg, 70%). 1H NMR 
(400 MHz, CDCl3) δ 7.73 – 7.68 (m, 2H), 7.35 – 7.30 (m, 2H), 4.98 (dq, J = 9.5, 2.4 Hz, 1H), 
3.88 (ddd, J = 13.9, 2.6, 1.0 Hz, 1H), 3.73 (ddd, J = 14.0, 2.5, 1.8 Hz, 1H), 3.55 – 3.47 (m, 
1H), 2.66 – 2.61 (m, 1H), 2.60 (q, J = 2.4, 1.6 Hz, 1H), 2.43 (s, 3H), 2.24 – 2.13 (m, 1H), 1.00 
(d, J = 6.4 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H), 0.89 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 143.6, 137.4, 133.1, 129.8, 129.3, 127.9, 55.0, 49.5, 37.2, 29.1, 22.8, 22.8, 21.7, 16.8. IR (film) 
ṽ 2958, 2928, 2868, 1462, 1344, 1160 cm-1. HRMS (ESI+) for C16H23NO2S [M+Na]
+: calcd 294.1522, found 
294.1521.  
1-(Cyclopent-1-en-1-ylmethyl)-1-methoxycyclohexane (11a). According to the Representative 
Procedure A from enyne 1f (24.8 mg, 0.11 mmol), colorless oil (20.4 mg, 93%). 
1H NMR (400 MHz, CDCl3) δ 5.43 – 5.36 (m, 1H), 3.18 (s, 3H), 2.36 – 2.26 (m, 4H), 
2.27 – 2.21 (m, 2H), 1.90 – 1.77 (m, 2H), 1.73 – 1.64 (m, 2H), 1.59 – 1.37 (m, 5H), 
1.32 – 1.16 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 140.7, 127.6, 75.6, 48.3, 37. 5, 36.9, 34.5, 32.6, 26.0, 
23.9, 22.1. IR (film) ṽ 3038, 2929, 2848, 1455, 1444, 1081 cm-1. HRMS (ESI+) for C13H22O [M+H]
+: calcd: 
195.1734, found: 195.1741. 
1-(Cyclopent-1-en-1-ylmethyl)-1-(methoxymethoxy)cyclohexane (11b). According to the Representative 
Procedure A from enyne S35 (26.6 mg, 0.10 mmol), flash chromatography (silica, 
hexanes/EtOAc 1:0 – 40:1 – 30:1), colorless oil (18.0 mg, 80%). 1H NMR (400 MHz, 
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CDCl3) δ 5.43 – 5.38 (m, 1H), 4.73 (s, 2H), 3.41 (s, 3H), 2.34 – 2.26 (m, 6H), 1.83 (m, 2H), 1.76 – 1.20 (m, 
10H). 13C NMR (101 MHz, CDCl3) δ 140.5, 128.1, 90.8, 77.8, 55.9, 39.5, 37.1, 35.5, 32.6, 25.9, 24.0, 22.5. 
IR (film) ṽ 2927, 2849, 1448, 1140, 1028 cm-1. HRMS (ESI+) for C14H24O2 [M+Na]
+: calcd: 247.1668, found: 
247.1671. 
tert-Butyl((1-(cyclopent-1-en-1-ylmethyl)cyclohexyl)oxy)dimethylsilane (11c). According to the 
Representative Procedure A from enyne S36 (31.4 mg, 0.09 mmol), colorless oil 
(19.0 mg, 69%). 1H NMR (400 MHz, CDCl3) δ 5.40 (m, 1H), 2.34 – 2.25 (m, 6H), 1.83 
(m, 2H), 1.70 – 1.57 (m, 2H), 1.53 – 1.24 (m, 8H), 0.88 (s, 9H), 0.08 (s, 6H). 13C NMR 
(101 MHz, CDCl3) δ 141.4, 127.9, 75.9, 43.8, 38.2, 37.4, 32.6, 26.3, 25.9, 24.2, 23.0, 18.6, -1.4. IR (film) ṽ 
2927, 2853, 1471, 1251, 1056, 769 cm-1. HRMS (ESI+) for C18H34OSi [M+Na]+: calcd: 317.2271, found: 
317.2271. 
3-((1-Methoxycyclohexyl)methyl)-2,5-dihydrofuran (11e). According to the Representative Procedure A 
from enyne S65 (25.9 mg, 0.11 mmol); light yellow oil (16.9 mg, 79%). 1H NMR 
(400 MHz, CDCl3) δ 5.60 – 5.52 (m, 1H), 4.67 – 4.61 (m, 2H), 4.61 – 4.55 (m, 2H), 
3.16 (s, 3H), 2.31 – 2.28 (m, 2H), 1.76 – 1.65 (m, 2H), 1.65 – 1.48 (m, 3H), 1.48 – 
1.37 (m, 2H), 1.34 – 1.21 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 136.4, 122.6, 77.9, 75.7, 75.2, 48.3, 34.3, 
34.1, 25.9, 22.1. IR (film) ṽ 2932, 2855, 1750, 1145, 1073 cm-1. HRMS (ESI+) for C12H20O2 [M+Na]
+: calcd: 
219.1357, found: 219.1355. 
Dimethyl 3-((1-methoxycyclohexyl)methyl)cyclopent-3-ene-1,1-dicarboxylate (11f). According to the 
Representative Procedure A from enyne S67 (24.6 mg, 0.07 mmol); 
colorless oil (16.8 mg, 77%). 1H NMR (400 MHz, CDCl3) δ 5.27 (m, 1H), 3.72 
(s, 6H), 3.17 (s, 3H), 3.03 – 2.96 (m, 4H), 2.22 (q, J = 1.2 Hz, 2H), 1.70 – 1.60 
(m, 2H), 1.57 – 1.45 (m, 3H), 1.46 – 1.35 (m, 2H), 1.31 – 1.17 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.9, 138.1, 124.2, 75.5, 59.6, 52.9, 48.3, 44.4, 40.6, 36.9, 3.3, 25.9, 22.1. IR 
(film) ṽ 2931, 2855, 1734, 1434, 1250 cm-1. HRMS (ESI+) for C17H26O5 [M+Na]
+: calcd: 333.1672, found: 
333.1673. 
1-Methoxy-1-((5-methoxycyclopent-1-en-1-yl)methyl)cyclohexane (11g). According to the 
Representative Procedure A from enyne S40 (30.5 mg, 0.12 mmol); colorless oil 
(13.7 mg, 53%). 1H NMR (400 MHz, CDCl3) δ 5.67 (m, 1H), 4.42 – 4.36 (m, 1H), 3.28 
(s, 3H), 3.21 (s, 3H), 2.45 – 2.35 (m, 2H), 2.29 – 2.18 (m, 1H), 2.17 – 2.04 (m, 2H), 
1.82 – 1.70 (m, 2H), 1.69 – 1.60 (m, 2H), 1.59 – 1.37 (m, 3H), 1.34 – 1.18 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 140.0, 132.0, 87.9, 75.7, 55.6, 48.3, 35.0, 34.2, 33.5, 30.3, 28.9, 26.1, 22.1, 
22.0. IR (film) ṽ 2931, 2853, 1456, 1260, 1083 cm-1. HRMS (ESI+) for C14H24O2 [M+Na]
+: calcd: 247.1668, 
found: 247.1668. 
2-((1-Methoxycyclohexyl)methyl)cyclopent-2-en-1-one (11h). According to the Representative 
Procedure A from enyne S41 (25.4 mg, 0.10 mmol); yellow oil (14.5 mg, 68%). 
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.43 (m, 1H), 3.22 (s, 3H), 2.64 – 2.55 (m, 2H), 
2.40 – 2.36 (m, 2H), 2.34 (q, J = 1.3 Hz, 2H), 1.71 – 1.60 (m, 2H), 1.58 – 1.49 (m, 1H), 
1.49 – 1.41 (m, 4H), 1.32 – 1.16 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 210.2, 160.8, 
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141.9, 75.4, 48.5, 34.2, 34.0, 30.1, 26.9, 25.9, 21.9. IR (film) ṽ 2931, 2856, 1700, 1444, 1074 cm-1. HRMS 
(ESI+) for C13H20O2 [M+Na]
+: calcd: 231.1355, found: 231.1357. 
3-((1-Methoxycyclohexyl)methyl)furan-2(5H)-one (11i). According to the Representative Procedure A 
from enyne S38 (27.1 mg, 0.11 mmol); light yellow oil (11.9 mg, 52%). 1H NMR 
(400 MHz, CDCl3) δ 7.29 (p, J = 1.6 Hz, 1H), 4.80 (q, J = 1.7 Hz, 2H), 3.22 (s, 3H), 2.46 
(q, J = 1.6 Hz, 2H), 1.75 – 1.67 (m, 2H), 1.59 – 1.42 (m, 5H), 1.36 – 1.20 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 175.3, 147.4, 129.6, 75.3, 70.5, 48.6, 34.1, 30.8, 25.8, 21.8. IR (film) ṽ 2931, 
2856, 1730, 1455, 1346, 1071 cm-1. HRMS (ESI+) for C12H18O3 [M+H]
+: calcd: 211.1329, found: 211.1329. 
((1-(2,5-Dihydrofuran-3-yl)-2-methylpropan-2-yl)oxy)triethylsilane (12a). According to the 
Representative Procedure A from enyne S62 (27.0 mg, 0.09 mmol), colorless oil 
(22.2 mg, 95%). 1H NMR (400 MHz, CDCl3): δ 5.54 – 5.50 (m, 1H), 4.67 – 4.57 (m, 4H), 
2.29 (s, 2H), 1.23 (s, 6H), 0.94 (t, J = 7.9 Hz, 9H), 0.63 – 0.54 (m, 6H). 13C NMR 
(101 MHz, CDCl3): δ 138.0, 122.6, 78.1, 75.5, 73.3, 43.7, 30.1, 7.2, 6.9. IR (film) ṽ 3412, 2973, 1735, 1370, 
1234, 1072, 1010, 901, 736 cm-1. HRMS (ESI+) for C14H28O2Si [M+Na]
+: calcd: 279.1751; found: 279.1753. 
3-(2-Methoxy-2-methylpropyl)-1-tosyl-2,5-dihydro-1H-pyrrole (12b). According to the Representative 
Procedure A from enyne S46 (34.8 mg, 0.1 mmol), colorless solid (24.0 mg, 78%). 
Single crystals suitable for X-ray analysis were grown by vapor diffusion of pentane 
into a saturated solution of product in CH2Cl2 at room temperature. mp.: 76-77 °C. 
1H NMR (400 MHz, CDCl3) δ 7.74 – 7.68 (m, 2H), 7.33 – 7.28 (m, 2H), 5.33 – 5.29 (m, 
1H), 4.14 – 4.05 (m, 4H), 3.14 (s, 3H), 2.42 (s, 3H), 2.17 (s, 2H), 1.04 (s, 6H). 13C NMR (101 MHz, CDCl3) 
δ 143.4, 136.7, 134.5, 129.8, 127.6, 121.7, 74.5, 57.6, 54.9, 49.4, 40.2, 24.8, 21.7. IR (film) ṽ 2962, 2860, 
2829, 1336, 1155, 1055 cm-1. HRMS (ESI+) for C16H23NO3S [M+Na]
+: calcd: 332.1291, found: 332.1288. 
3-(2-((tert-Butyldimethylsilyl)oxy)-2-methylpropyl)-1-tosyl-2,5-dihydro-1H-pyrrole (12c). According to 
the Representative Procedure A from enyne S47 (44.8 mg, 0.10 mmol); colorless 
solid (31.0 mg, 76%). 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.68 (m, 2H), 7.33 – 7.28 (m, 
2H), 5.34 – 5.27 (m, 1H), 4.14 – 4.03 (m, 4H), 2.42 (s, 3H), 2.15 (s, 2H), 1.13 (s, 6H), 
0.83 (s, 9H), 0.03 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 143.4, 137.1, 134.6, 129.8, 
127.6, 121.7, 73.5, 57.7, 54.8, 45.0, 30.0, 26.0, 21.7, 18.1, -1.9. IR (film) ṽ 3039, 2928, 2856, 1337, 1161, 
1102 cm-1. HRMS (ESI+) for C21H35NO3SSi [M+Na]
+: calcd: 432.1999, found: 432.2000. 
3-(2-Methoxybutyl)-1-tosyl-2,5-dihydro-1H-pyrrole (12d). According to the Representative Procedure A 
from enyne S49 (41.8 mg, 0.12 mmol), light brown oil (13.3 mg, 36%). 1H NMR 
(400 MHz, CDCl3) δ 7.71 (d, J = 7.9 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 5.32 (s, 1H), 4.13 
– 3.99 (m, 4H), 3.25 (s, 3H), 3.16 – 3.09 (m, 1H), 2.42 (s, 3H), 2.17 (d, J = 5.9 Hz, 2H), 
1.48 – 1.31 (m, 2H), 0.83 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 143.5, 
137.0, 134.4, 129.8, 127.6, 120.3, 80.5, 57.1, 56.6, 55.1, 32.8, 25.8, 21.7, 9.3. IR (film) ṽ 2967, 2930, 1598, 
1341, 1160 cm-1. HRMS (ESI+) for C16H23NO3S [M+Na]
+: calcd: 332.1291, found: 332.1291. 
3-(2-Methoxyethyl)-1-tosyl-2,5-dihydro-1H-pyrrole (12e). According to the Representative Procedure A 
from enyne S51 (34.8 mg, 0.11 mmol), colorless oil (3.5 mg, 11%). 1H NMR (400 MHz, 
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CDCl3) δ 7.74 – 7.68 (m, 2H), 7.34 – 7.29 (m, 2H), 5.34 (hept, J = 1.6 Hz, 1H), 4.13 – 4.05 (m, 2H), 4.06 – 
4.01 (m, 2H), 3.42 (t, J = 6.3 Hz, 2H), 3.30 (s, 3H), 2.43 (s, 3H), 2.31 – 2.23 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 143.5, 137.0, 134.5, 129.9, 127.6, 119.6, 70.5, 58.8, 56.8, 55.1, 29.3, 21.7. IR (film) ṽ 2921, 2863, 
1341, 1160, 1100 cm-1. HRMS (ESI+) for C14H19NO3S [M+H]
+: calcd: 282.1158, found: 282.1158. 
3-((2-methyl-1,3-dioxolan-2-yl)methyl)-1-tosyl-2,5-dihydro-1H-pyrrole (13). According to the 
Representative Procedure A from enyne S55 (36.0 mg, 0.10 mmol), colorless oil 
(17.3 mg, 54%). 1H NMR (400 MHz, CDCl3) δ 7.75 – 7.69 (m, 2H), 7.34 – 7.28 (m, 2H), 
5.39 (m, 1H), 4.09 (s, 4H), 3.91 – 3.84 (m, 2H), 3.84 – 3.77 (m, 2H), 2.41 (s, 3H), 2.35 
(s, 2H), 1.18 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 143.4, 135.2, 134.4, 129.8, 127.6, 
122.4, 109.0, 64.8, 57.3, 55.1, 38.9, 23.9, 21.6. IR (film) ṽ 2983, 2875, 1341, 1161, 1046 cm-1. HRMS (ESI+) 
for C16H21NO4S [M+Na]
+: calcd: 346.1084, found: 346.1083. 
3-(2,3-bis((tert-Butyldimethylsilyl)oxy)-2-methylpropyl)-1-tosyl-2,5-dihydro-1H-pyrrole (14). According 
to the Representative Procedure A from enyne S53 (55.0 mg, 0.09 mmol), 
colorless oil (34.2 mg, 67%). 1H NMR (400 MHz, CDCl3) δ 7.74 – 7.68 (m, 2H), 
7.33 – 7.28 (m, 2H), 5.32 (m, 1H), 4.11 – 4.01 (m, 4H), 3.26 – 3.20 (m, 2H), 2.42 
(s, 3H), 2.27 – 2.21 (m, 1H), 2.20 – 2.11 (m, 1H), 1.10 (s, 3H), 0.86 (s, 9H), 0.83 
(s, 9H), 0.03 (s, 3H), 0.03 (s, 3H), 0.00 (s, 3H), -0.02 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 143.3, 136.6, 
134.5, 129.8, 127.7, 121.8, 76.2, 69.8, 57.9, 54.8, 39.6, 26.1, 26.0, 25.4, 21.7, 18.4, 18.3, -1.7, -1.8, -5.4, 
5.4. IR (film) ṽ 2954, 2929, 2856, 1163, 1096 cm-1. HRMS (ESI+) for C27H49NO4SSi2 [M+Na]
+: calcd: 
562.2813, found: 562.2814. 
4-Methoxy-4-methyl-1-octylcyclopent-1-ene (15). According to the Representative Procedure A from 
enyne S75 (30.3 mg, 0.11 mmol), colorless oil (25.2 mg, 98%). An aliquot was further 
purified by HPLC. 1H NMR (400 MHz, CDCl3) δ 5.23 (hept, J = 2.2 Hz, 1H), 3.20 (s, 3H), 
2.58 – 2.45 (m, 2H), 2.28 – 2.12 (m, 2H), 2.05 – 1.97 (m, 2H), 1.46 – 1.35 (m, 2H), 1.33 
(s, 3H), 1.30 – 1.23 (m, 10H), 0.87 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 142.9, 121.0, 83.9, 50.7, 47.0, 44.5, 32.0, 31.5, 29.6, 29.6, 29.4, 27.7, 25.6, 22.8, 
14.3. IR (film) ṽ 2959, 2924, 2854, 1461, 1077 cm-1. HRMS (ESI+) for C15H28O [M+Na]+: calcd: 247.2032, 
found: 247.2032. 
Dimethyl 3-((1-methoxycyclohexyl)methyl)cyclohex-3-ene-1,1-dicarboxylate (18). According to the 
Representative Procedure B from enyne 17 (29.3 mg, 0.08 mmol), colorless 
oil (16.9 mg, 65%). 1H NMR (400 MHz, CDCl3) δ 5.37 (m, 1H), 3.71 (s, 6H), 3.18 
(s, 3H), 2.58 (s, 2H), 2.13 (s, 2H), 2.09 (s, 4H), 1.68 (dt, J = 13.4, 4.0 Hz, 2H), 
1.60 – 1.36 (m, 5H), 1.29 – 1.14 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 172.3, 
131.9, 123.8, 75.8, 53.9, 52.7, 48.3, 44.0, 35.4, 34.3, 27.3, 26.0, 22.8, 22.1. IR (film) ṽ 2931, 2852, 1733, 
1435, 1253 cm-1. HRMS (ESI+) for C18H28O5 [M+Na]
+: calcd: 347.1829, found: 347.1830. 
4-((1-Methoxycyclohexyl)methyl)-1-tosyl-1,2,3,6-tetrahydropyridine (19). According to the 
Representative Procedure B from enyne S32 (33.7 mg, 0.08 mmol), colorless 
oil (17.9 mg, 59%). 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.64 (m, 2H), 7.33 – 7.28 
S54 
 
(m, 2H), 5.36 – 5.28 (m, 1H), 3.60 – 3.52 (m, 2H), 3.14 (t, J = 5.7 Hz, 2H), 3.13 (s, 3H), 2.42 (s, 3H), 2.28 – 
2.22 (m, 2H), 2.07 (s, 2H), 1.68 – 1.31 (m, 6H), 1.31 – 1.11 (m, 3H), 0.96 – 0.81 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 143.5, 133.6, 133.5, 129.7, 127.9, 120.0, 75.7, 48.2, 45.0, 43.2, 42.7, 34.4, 29.9, 25.9, 
22.0, 21.7. IR (film) ṽ 2929, 2854, 1458, 1341, 1161 cm-1. HRMS (ESI+) for C20H29NO3S [M+Na]
+: calcd: 
386.1760, found: 386.1758. 
5-Methoxy-5-methyl-1-octylcyclohex-1-ene (20). According to the Representative Procedure B from 
enyne S77 (31.0 mg, 0.11 mmol), colorless oil (22.7 mg, 82%). 1H NMR (400 MHz, 
CDCl3) δ 5.40 – 5.32 (m, 1H), 3.24 (s, 3H), 2.20 – 2.05 (m, 2H), 2.04 – 1.88 (m, 4H), 
1.73 – 1.65 (m, 1H), 1.57 – 1.48 (m, 1H), 1.38 (m, 2H), 1.26 (m, 10H), 1.16 (s, 3H), 
0.91 – 0.85 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 135.9, 119.4, 73.5, 49.0, 39.9, 37.9, 
32.1, 31.9, 29.7, 29.5, 29.5, 27.8, 23.5, 22.8, 22.7, 14.3. IR (film) ṽ 2923, 2853, 1462, 
1369, 1095 cm-1. HRMS (CI) for C16H30O [M+NH4]
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